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The use of nanotechnology in medical science, in short nanomedicine, is currently a bursting 
field of research. The involvement of nanomaterials in medicine allows the development of 
new, potent therapeutic agents that empower the conventional therapies by acting as drug 
carriers, imaging agents, biomarker recognition agents for early diagnostics,1 scaffolds for 
regenerative medicine,2, 3 or possess intrinsic therapeutic properties and have potential as 
stand-alone drugs.4-6 The use of nanomaterials for this scope allows the optimization and 
tailoring of preexisting therapies, as well as reducing their side effects, provide combined 
therapeutic and diagnostic properties (theranostics),7-9 as well as brand new therapeutic 
strategies. Their incorporation into nanodevices allows the screening and shielding of living 
tissues with unprecedented accuracy and programming.10 Thus, the concept of nanomedicine 
is evolving and includes in its definition any use of nanosized materials, for the improved 
treatment of cancer,11 auto-immune 12 or degenerative diseases.13  
Several different classes of nanomaterials are encountered in nanomedicine, as they vary 
between polymeric,14 lipidic,15 inorganic (silicon- 16 or metal-based),17 or carbonaceous.18 A 
combination of these materials is also encountered, to combine the advantages provided by 
the single precursor materials together in one nanoparticle.19 Depending on the desired 
application, researchers developed nanomaterials with tailored physicochemical 
characteristics and bioreactivities, to function as next generation therapeutics. Nanomaterials 
structures span over many dimensionalities, starting from zero-dimensional nanoparticles, to 
one-dimensional nanotubes or nanowires,20, 21 to two dimensional nanosheets or 
nanomembranes,22 all to be integrated into complex three-dimensional devices.23 An overview 
of the various nanosystems is shown in Fig. 1.1. The hierarchies in multidimensionality allow 





Fig. 1.1 Overview of nanoparticles employed in different classes of applications in 
nanomedicine. Reproduced with permission from Cai et al.10 Copyright 2017 Wiley-VCH.  
The use of macromolecules as drug carriers help vectoring the drug inside the target tissues, 
thereby improving its biodistribution profile, acting as a (sometimes self-immolating) skeleton, 
leading to an in situ sustained delivery of the encapsulated drug. In this way, nanocarriers 
inhibit the drug free diffusion by physical entrapment, allowing the single drug dose to stay 
longer inside the therapeutic window, as shown in Fig. 1.2.24 Analogously, nanoparticle-drug 
conjugates allow the accumulation in selected tissues and the in situ release of the drug from 
the conjugate, by selective cleavage of self-immolating bonds.25 Therefore, nanocarriers are 
responsible for extending the drug circulation and its blood retention, reduce immunogenic 
reactions, decrease systemic toxicities, and improve drug stability, thus effectively reducing 





Fig. 1.2 Release kinetics by nanomedicine compared to conventional drug administration and 
their behavior in blood as shown from the therapeutic window. Modified with permission from 
Yi et al., copyright 2015 Royal Society of Chemistry.27 
These beneficial properties of drug nanocarriers were found not only to improve the efficacy 
of small drugs, but also for biomacromolecules: therapeutic proteins and nucleic acids (DNA, 
siRNA) are provided with sustained, site-specific release, and they showed improved stability 
towards enzymatic degradation and thermal denaturation, when encapsulated into 
nanoparticles.28  
The imaging of biological tissues may also be accomplished with the use of nanomaterials, 
provided that high contrast materials are involved, from optical contrast, high electron density 
(plasmonic Au or Ag nanoparticles),29 high fluorescence quantum yields (quantum dots,30 
organic dyes31), to magnetic contrast using magnetic nanoparticles,32, 33 positron-emitting 
radioactive materials,34, 35 or ultrasound.36 Macromolecular imaging agents were developed for 
their improved performances in vivo, to improve the biocompatibility of high contrast agents by 
embedding them onto tailored nanoparticles, as well as increase focusing and resolution of the 
imaging technique.37 Multimodal imaging techniques further increases precision and image 
resolution, by combining multiple contrast agents onto one single macromolecular scaffold.6 In 
theranostic agents, the diagnostic moieties and therapeutic activities are colocalized inside a 
single nanoparticle, allowing an unprecedented precision of therapy and diagnostics.7  
Both imaging agents and drug carrier nanoparticles can be directed towards the site of action 
by either active or passive targeting strategies.38 Both are used in an attempt to address the 
nanoparticle towards its site of action and accumulate in the diseased tissues, thereby further 
reducing the therapy’s side effects. Active targeting may exploit specific protein or cell 
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interactions with the macromolecule’s tunable surface chemistry, using common 
bioconjugation pathways (avidin – biotin, transferrin – TfR1, antibody – antigen, sialic acid – 
carbohydrate, folic acid – RFC, RGD peptide – α2β3 integrin) with receptors that are 
overexpressed on cancer cells.39 Passive targeting exploits the physical properties of 
nanoparticles to specifically deliver the drug into tissues that are able to behold nanosized 
materials, due to the enhanced permeation and retention (EPR) effect. This effect is 
responsible for nanoparticle efficacy in tumor tissues, as they exhibit hyperpermeability, due 
to irregular tissue growth, arising from leaky vasculature and missing lymphatic drainage. A 
nanosized particle would selectively penetrate such tissues, and avoid the compact healthy 
tissues, that have too small pores.40  
1.1.1 Nanogel Architectures 
The use of polymers in nanomedicine comprises many different polymeric architectures, 
leading to new stand-alone drugs, drug-polymer conjugates, polyplexes, polymeric micelles, 
nanoparticles, and nanogels. Nanogels are a class of polymeric nanoparticles, formed by 
crosslinking of hydrophilic polymeric precursors.41 Their marked propension to swell in water 
solutions facilitate the encapsulation of hydrophilic molecules, thus favoring their use as drug 
delivery agents. Due to their usually soft nature, they are well accommodated by soft biological 
tissues and have a distinct tendency to be uptaken by cells, another advantageous feature for 
drug delivery.42 The ease of the nanogel’s surface functionalization make them especially good 
candidates for exploiting active targeting strategies by bioconjugation,43 and theranostic 
agents, by combining organic dyes or inorganic contrast agents.19 Multiple drugs may be 
codelivered by nanogels specifically in situ, in a synergistic approach to overcome multidrug 
resistance and reduce the effective dosages. The combination of nanogels with other 
nanomaterials (both polymeric and inorganic) allows the formation of so-called hybrid 
nanogels, which retain the advantageous properties of all single components, in the form of 
nanogels, polymers or inorganic constituents, with fine control on the resulting hybrid nanogel 
morphology. The incorporation of magnetic, plasmonic, or carbonaceous nanomaterials led to 
hybrid nanogels as agents for imaging, photodynamic therapy, photothermal therapy, drug 
delivery, or a combination of these.44, 45 
Polymer-nanogel composites can be subdivided into two different morphologies, being core-
shell, or (semi-)interpenetrated nanogels. While both architectures show multicompartimental 
structures, (semi-)interpenetrated nanogels exhibit heterogeneous, isotropic structures, while 
core-shell nanogels have distinct radially distributed homogeneous layers. These next 
generation nanogels show multifunctional structures and may in general improve the 
performance of standard nanogels.  
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In core-shell nanogels, the reactivity as well as the physicochemical characteristics are 
dictated concertedly by all coexisting layers of the nanogel. The most common core-shell 
strategy is the grafting of poly(ethylene glycol) on the surface of nanoparticles, in a process 
known as PEGylation, which is regarded as the golden standard for improving biocompatibility 
of nanoparticles.46 
Interpenetrated nanogels are provided by the colocalization of more than one independent 
polymer network, to give nanogels with multiple components that are not chemically bound to 
each other, although they cannot be separated by shear stress, rather only by chemical 
reactions.47 As a result, interpenetrated nanogels retain all properties of the single precursor 
polymeric networks, which is an advantage over core-shell structures, while the relative 
amounts of the single networks may be adjusted according to the designed application. Semi-
interpenetrated nanogel structures exhibit analogous properties, while they differ from 
interpenetrated nanogels, due to their non-crosslinked network within the nanogel.48 Both 
categories of polymer-nanogel composites have specific advantages in nanomedicine, while 
core-shell may result in particles exhibiting improved targeting abilities, interpenetrated 
nanogels are developed as high affinity drug delivery agents.49  
The rational design of multifunctional nanogels having different architectures has a noteworthy 
effect on the optimization of their performance as nanopharmaceutics. The employment of 
combined nanomaterials widens the applications of the resulting hybrid nanogel, as shown in 
Fig. 1.3. By incorporation of anisotropic Au or Ag nanoparticles, the nanogels become near-
infrared (NIR) absorbing. This peculiar property arises from the plasmonic character of Au and 
Ag nanoparticles, that can be exploited for obtaining plasmonic nanogels for photothermal 
therapy and / or imaging agents. The NIR window in the electromagnetic spectrum (λ = 700 – 
1300 nm) is useful in medicine, since either water or other components of biological tissues do 
not absorb in this region.50 The irradiation of plasmonic nanogels via NIR laser may generate 
hyperthermia in localized tissues at a depth of 10 cm.51 Other advanced nanomaterials may 
be employed, to combine their striking properties with those of nanogels. Magnetic Fe 
nanoparticles may be embedded in the nanogel architecture, to give magnetic nanogels, as 
cell sorting agents, magnetic resonance imaging (MRI) agents, or hyperthermia agents by 
application of an alternating magnetic field.52 Analogously, carbonaceous nanomaterials were 
used to confer enhanced stiffness, conductivity and NIR activity to nanogels.49 
The choice of polymer chemistry is also fundamental for achieving functional nanogels, not 
only regarding their biocompatibility, but also to obtain “smart”, reactive nanogels that can tune 
their properties according to the desired physicochemical stimuli. The design of advanced 
nanomaterials for medicine led to the development of “smart” nanogels, that are reactive 
towards the surrounding environmental conditions, by showing a phase transition regulated by 
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changes in temperature, pH, ionic strength, reducing conditions, glucose concentration, light, 
magnetic field, or ultrasound.49 Many of these stimuli may conform to relevant biological 
interactions and can therefore interact with target tissues to benefit the therapy’s efficacy, 
through careful tuning of the characteristics of the employed “smart” materials. Other stimuli 
like light and magnetic field can be applied externally, towards the target tissue to let the 
nanogel react in situ, after successful delivery of the bioactive from the nanogel. A sequential 
approach may be applied, for the delivery of multiple drugs in separated time instances, by 
using nanogels that react to multiple stimuli.  
 
 
Fig. 1.3 Overview of nanogel architectures and their advanced functionalities 
Thermoresponsive nanogels are the most researched for their applicability in various 
therapeutic instances, due to the readily available thermoresponsive polymers, as the ones 
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Fig. 1.4 Common LCST-type thermoresponsive polymeric precursors for the synthesis of 
thermoresponsive nanogels. 
Thermoresponsive polymers exhibit a sharp phase transition in water, regulated by the loss of 
solubility upon reaching of a critical temperature. Polymers with a lower critical solution 
temperature (LCST) are the most common, and they show solubility in water only below this 
temperature, with a negative solvation entropy, leading to coil-to-globule transition of the 
polymer chain above the LCST. Thermoresponsive behavior may be subdivided in three 
different modes: a type-I thermoresponsive polymer follows a typical Flory-Huggins behavior, 
leading to concentration and molecular weight-dependent LCST values.53 Type-II polymers do 
not show vast LCST variations according to polymer concentration or molecular weight, while 
type-III polymers show a bimodal thermoresponsive behavior in water.54 In other less common 
instances, polymers exhibit an upper critical solution temperature (UCST), with a positive 
solvation entropy, leading to soluble polymers above this value.55 Polymers with a CST close 
to the physiological 37 °C are those which show extended applications in nanomedicine. The 
CST values can be fine–tuned by changing the hydrophilic / hydrophobic ratio of the polymers 
in question. The most used thermoresponsive polymer is poly(N-isopropylacrylamide) 
(pNIPAM), which shows a LCST type-II behavior, with the transition at a constant 32 °C, 
independently from the polymer chain length / concentration. The LCST close to that of the 
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human body makes pNIPAM particularly interesting for biomedical purposes. The 
copolymerization with hydrophilic comonomers, such as acrylic acid or acrylamide would lead 
to increase of the LCST towards the body temperature. The copolymerization of pNIPAM with 
hydrophobic comonomers such as N-tert-butylacrylamide would decrease the resulting 
LCST.56 Poly(N-isopropylmethacrylamide) (pNIPMAM) shows a LCST type-II behavior at a 
higher 46 °C. Both pNIPAM and pNIPMAM may be copolymerized, to obtain intermediate 
LCST values closer to the desired 37 °C. Other examples include 2-(2-methoxyethoxy) ethyl 
methacrylate (MEO2MA), oligoethylene glycol methacrylate (OEGMA) and their copolymers, 
to obtain polymers with tunable LCST.57 Poly(2-(dimethylamino)ethyl methacrylate) 
(pDMAEMA) shows dual pH- and thermoresponsiveness,58 while poly(glycidyl methyl ether-
co-ethyl glycidyl ether) (p(GME-c-EGE)) exhibits tunable LCST according to the EGE / GME 
ratio, also named thermoresponsive polyglycerol (tPG).59 In turn, poly(N-vinylcaprolactam) 
(pVCL) is another example of biocompatible polymer, showing a type-I behavior, its LCST 
value depending on polymer length / concentration in aqueous solution.53 
By crosslinking such thermoresponsive polymers, one can form nanogels with reversible 
phase change around their CST. The CST proper of polymers contributes to the overall 
nanogel phase transition temperature (VPTT). The associated reversible coil-to-globule phase 
transition may promote the release of the encapsulated cargo from the nanogels in a controlled 
fashion. Thermoresponsive nanogels may be subjected to phase change upon entering 
cancerous tissues, that exhibit a temperature gradient with the surroundings, due to increased 
metabolic rates. A rational tuning of the critical solution temperature of the nanogels may allow 
the temperature gradient to be used as trigger for drug release. By incorporation of NIR - active 
nanoparticles inside thermoresponsive nanogels, a similar hyperthermia effect may be 
activated remotely, via NIR laser irradiation. This may be combined with the thermoresponsive 
polymer network, to get remotely controlled nanogel shrinkage for improved in situ drug 
delivery. 
pH-responsive polymers are as well used as nanogel precursors, as they may also act as 
selective delivery agents towards cancerous tissues, that are slightly more acidic than healthy 
tissues, or towards specific intracellular compartments that are naturally more acidic, such as 
endosomes and lysosomes. Other stimuli, such as reducing conditions or concentration of 
proteolytic enzymes reflect the need of nanoparticles that degrade specifically after their 
uptake into the cytosol. Glucose concentration was as well investigated as stimulus for 
diabetes therapy, through the use of phenylboronic acid derivatives as nanogel components, 




1.1.2  Dendritic Architectures in Nanomedicine 
Another class of functional materials that were implemented for biomedical applications are 
dendrons / dendrimers. These macromolecules possess a repetitive branched tree-like 
structure, that exhibit exponential increase in end points, according to the generation used 
(number of repetitive branchings). The presence of an array of repetitive end groups favor the 
multivalent binding of (macro)molecules to dendrimers. By increasing the generation number 
and end-group chemistry, one could tune the dendron’s self-assembly features, to give rise to 
specific, unique three-dimensional arrangements of macromolecules, ranging from micelles to 
vesicles, cylindrical micelles to helical ribbons, as well as nanotubes.60 This property of 
dendrons make them suitable as nanocarriers, as well as for the development of sensing 
agents, catalysts, vaccines, agents for MRI contrast, neutron capture, gene therapy, or 
photodynamic therapy.61-63 Moreover, the rigidity imposed by the structure of dendrimers opens 
wide hollow gaps in the dendrimer core, a useful feature for the efficient loading of guest 
molecules, both hydrophobic or hydrophilic, according to the core chemistry. Their 
incorporation onto other nanomaterials facilitates their solubilities, inhibiting interchain 
aggregation of linear polymers.64 Dendritic structures often exhibit improved characteristics as 
drug delivery agents as compared to their linear counterparts. The industrial handling of 
dendritic materials is also facilitated, due to their decreased solution viscosities. Dendrimers 
and dendrons are monodisperse architectures, they differ from polydisperse architectures 
(hyperbranched, dendrigrafts, linear – dendritic) for their synthetic methodologies and overall 
physicochemical characteristics. Dendrimers are globular nanoparticles which bonds stem 
from a single focal point (core), radially expanding with regular branched units. Dendrons are 
similarly originating as radial expansion of branched units, however they exhibit anisotropic 
expansion of the branching units in one favored direction. The intrinsically regular dendritic 
structures yield monodisperse nanoparticles (PDI = 1.0), a useful feature for high-end 
technologies. The downside relies in the complexity of the synthesis of a perfect dendron / 
dendrimer, according to the repetitive chemistry needed to increase the generation number, 
leading to elevated costs and high amounts of waste products. Hyperbranched polymers 
exhibit irregular dendritic structures and polydispersity, as they are obtained by non-controlled 
polymerization techniques. This leads to polymers maintaining many of the dendritic 
properties, however providing at the same time much lower production costs. Fig.  1.5 provides 






Fig. 1.5 Overview of common dendritic structures with versatile applications in nanomedicine. 
Hyperbranched polyglycerol is an example of a dendritic structure, that showed versatility for 
the generation of biocompatible macromolecules and nanogels for therapeutic purposes.65 The 
synthesis of dendritic polyglycerol (dPG) affords via controlled, anionic ring-opening 
polymerization of glycidol. The hyperbranched structure allows the packed polyhydroxyl 
surface to mimic that of water, is therefore highly soluble and biocompatible. Its tunable size 
allows for a controlled formation of nanoparticles in the order of 3-10 nm, which size allows a 
fast renal excretion upon systemic administration of dPG. Its ease of functionalization was 
exploited for its incorporation inside stimuli-responsive nanogel structures, in order to improve 
their bioavailability and colloidal stability, even above the LCST of thermoresponsive polymers. 
They show a broad versatility for their application in anticancer therapy, as well as for topical 
agents for the treatment of skin diseases 57, 66-69 or as smart components embedded in porous 
surfaces for the controlled release of proteins.70 Thermoresponsive dPG-pNIPAM nanogels 
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developed by the Calderón group show tunable LCST values between 32.5 °C to 34.6 °C, 
according to the adopted feed ratio of dPG. The nanogels were successfully internalized by 
human U-937 cells, and show low cytotoxicity.71 Dual-responsive nanogels were obtained by 
copolymerization with pH-sensitive 2-(dimethylamino)ethyl methacrylate (DMAEMA), to 
provide tunable LCST ranging between 37 - 41 °C, and enhanced loading of doxorubicin and 
methotrexate.58 In another report by the Calderón group, NIR-active poly(aniline) was semi-
interpenetrated into dPG-pNIPAM nanogels, to provide light sensitivity to the nanogels, useful 
for promoting PTT in vivo upon NIR laser irradiation of tumor cells.72 Sections 3.1 - 3.3 and 
3.5 in this thesis regard the use of dPG-based thermoresponsive nanogels for anticancer 
therapy and their interactions with blood proteins. 
Newkome-type dendrons are a class of polyamidic, dendritic structures that allow easy surface 
functionalization.63 They show a 1 -> 3 C-branching pattern (Fig. 1.5, bottom right) which 
impairs high density of functional groups, together with dimethylene spacers that allow high 
flexibility and avoid steric overcrowding. These materials showed a broad applicability in many 
technological fields, ranging from catalysis,73, 74 to biosensing,75 surface self-assembly 76 and 
nanomedicine. Newkome-type dendrimers showed interesting features as host-guest 
interactions promoters, for the solubilization of antichagasic compound (2’-(benzo[1,2-c] 1,2,5-
oxadiazol-5(6)-yl (N-1-oxide) methylidene]-1-methoxy methane hydrazide)77 or the antitumoral 
benzimidazole carbamate,78 while the grafting of both polar and apolar versions of Newkome 
dendrons was successful for the synthesis of hybrid Au nanoparticles 79 as well as dendronized 
chitosan films for wound repair and antibacterial activity.80 In another case study, Newkome 
dendrons were incorporated onto latex beads and functionalized with mannose to obtain 
glycodendrimers, that were able to modulate CD3+ T-cell proliferation to mimic Leishmania 
activity.81 Acid-functionalized Newkome dendrons allow the generation of pH-responsive, 
dendritic linear polymers that are biocompatible and are used as components of 
thermoresponsive nanogels, both by semi-interpenetration and copolymerization, as shown in 




1.1.3 Biosafety Issues in Nanomedicine 
The increasingly growing field of nanotechnology reaches over several different fields of 
applications, from cosmetic to medicine, to high-end consumer electronics, sensing, among 
others. Many commercially available nanoparticle formulations provide however no long-term 
solution to the issue of sustainable life-cycles and toxicities after prolonged exposures. It is 
already well known that the inhalation of microparticles found in the atmosphere as byproducts 
of combustion constitutes an important health threat to humans, due to the interaction with the 
alveolar tissues in the lungs.82 While some information is provided regarding health issues of 
industrial micro- / nanoparticles and their undesired uptake in biological systems, less is 
currently disclosed about nanoparticle safety in medicinal applications.  
Like any other pharmaceutic agent, a Food and Drug Administration Agency (FDA) approval 
is required for nanoparticle applications in humans. As of November 2017, 57 drug 
nanoformulations were approved by the FDA, with other 81 candidates involved in different 
stages of clinical trials. This framework is in rapid expansion, showing a 3-fold increase in 
clinical trials between 2013 and 2016.83 Most of the approved formulations are composed by 
simple nanoparticle systems, or small drug-polymer conjugates, mostly obtained by 
PEGylation, for achieving a prolonged circulation in the bloodstream.84 These formulations 
differ greatly for their chemical nature, ranging from polymeric or metallic nanoparticles, 
liposomes, to recently approved micelles or protein-based nanoparticles. Most approved 
formulations are administered intravenously or orally, while rare cases of topical applications 
are present as well. A noteworthy increase in clinical trials of nanotherapeutics / imaging 
agents today signifies a likely expansion of the actual list of approved formulations in the next 





Fig. 1.6 a) FDA approved nanomedicines listed by category and year of approval until 2015; 
b) classification of approved nanomedicines by category; c) clinical trials ongoing for 
nanomedicines according to their starting date; d) classification of nanomedicines currently 
involved in clinical trials for FDA approval, by category. Reproduced with permission from Bobo 
et al., copyright 2016 Springer. 83 
In average, an FDA approval procedure requires 11 years of clinical investigations, to cover 
four stages of clinical trials, which overall account for $1 billion expenses for every candidate. 
During the four stages of clinical trials however, nanoparticle-based treatments often fail, due 
to issues posed by unexpected biodistributions and / or nanoparticle accumulation in healthy 
organs, mostly those belonging to the mononuclear phagocyte system (MPS), namely liver, 
kidneys and spleen.  
A new approach in nanosafety is thus needed to understand the issues of wrongful in vivo 
biodistribution, at a molecular level. The strong surface interactions of nanoparticles with the 
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surroundings is what ultimately has to be investigated in vitro, to understand the so-called bio-
nano interface, before having to recur to actual in vivo tests. 
1.2. Blood Compatibility of Nanoparticles 
A successful nanoparticle design for in vivo applications should comply to a few biophysical 
principles, regarding their compatibility at the bio-nano interface. Nanoparticle size, surface 
chemistry, hydrophobicity, roughness and shape are the primary aspects to take into 




Fig. 1.7 Biophysical assessments of nanoparticle safety and blood availability. Reproduced 
with modifications from Nel et al., copyright 2009 MacMillan Publishers Limited. 85 
Positively charged nanoparticles are regarded as cytotoxic, due to strong interactions with the 
negatively charged cell membrane, as a consequence they are as well more likely to induce 
hemolysis and platelet aggregation.86 A common example for this behavior was shown by 
poly(amidoamine) (PAMAM) dendrimers, that are used as stand-alone drugs, as they 
intrinsically exhibit high cytotoxicity.87 By reducing cationic densities through coating with 
hydrophilic polymers (PEGylation), or by using negatively charged or neutral / zwitterionic end-
groups, dendrimers and nanoparticles in general show improved biocompatibility and lower 
toxicities.88  
Nanoparticle size is another crucial factor that influences in vivo bioavailability. Particles 
smaller than 10 nm will be efficiently cleared by the kidneys, and will not be circulating in the 
bloodstream after some hours following administration. Particles bigger than 200 nm will be 
likely be uptaken by the MPS, to be conveyed towards liver and spleen and accumulate in 
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healthy tissues, as they are not able to escape through the biliar ducts that are only 30 nm 
wide. Similarly, hydrophobic nanoparticles show van der Waals interactions at a protein level, 
leading to recognition by the reticuloendothelial system (RES) and cleared from blood 
circulation.85 Therefore, an ideal nanoparticle to show prolonged circulation and accumulate 
into tumor tissues should rely in a size range between 30 – 200 nm and have hydrophilic 
character by some degree.  
All the aforementioned physical characteristics define the nanoparticle’s way of interacting with 
tissues. Since nanoparticles exhibit extremely high surface densities, when compared to their 
bulk counterparts, they promote the unspecific binding of (macro)molecules onto the 
nanoparticles’ surface. As a result, unpredictable short- and long-term effects on the health of 
the individual are observed and documented.89 In order to investigate those effects, studies 
about blood compatibility are needed, where nanoparticles should be tested for their ability to 
bind blood components, especially proteins and lipids. While also the cellular component of 
blood may interact with nanoparticles, especially positively charged nanoparticles that 
generate hemolysis, major health issues are arising from the unspecific binding of blood 
proteins, to form a so-called “protein corona”. 
1.2.1.  Biological Implications of the Protein Corona 
The human blood is the medium responsible for the circulation of nutrients, oxygen, signaling 
agents and molecular precursors of tissues in the body, it constitutes roughly 35% of the overall 
extracellular fluids. Its complex composition shows a 45% amount of cellular components, 
which are subdivided in erythrocytes, leukocytes and platelets. The cell-free component 
accounts for the remaining 55% of the blood volume, is also known as plasma. In human 
plasma, approximately 3700 different proteins are present, in a broad range of concentrations 
(10-8 to 102 g/L) and molecular weights (5 to 700 kDa). Due to the very high protein 
concentration (60 – 80 g/L according to patient characteristics / water intake) and the extremely 
high surface density of colloidal nanoparticles, the binding of proteins is a spontaneous and 
fast phenomenon, when in contact with blood. The kinetics of binding are also very fast, 
ranging from 10-4 s to 103 s for the binding of single proteins onto nanoparticles.90 The 
supramolecular protein corona obtained on the surface of nanoparticles has a strong impact 
on the biodistribution and overall on the biological identity of nanoparticles. 
New surface interactions arise with signaling / immune / cell membrane proteins, thus changing 
the reactivity of nanoparticles unpredictably. For example, the binding of immune proteins, 
immunoglobulins and complement proteins, may trigger an immune response, which leads to 
sequestration of nanoparticles from the bloodstream and delivery into the MPS.91, 92 The 
process is also called opsonization, and the proteins involved in the process are called 
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opsonins.93 Opsonization is not recommended for a nanoparticle-based therapy, unless the 
purpose is the effective targeting of the organs belonging to the MPS. Another detrimental 
effect may arise from the binding of prothrombin, that signals initial blood coagulation.94 On the 
other hand, carrier proteins in the blood enhance the bioavailability of small drugs, as well as 
bind to hydrophilic nanoparticles, thereby enhancing their circulation time in blood and 
preventing their sequestration to the MPS. These proteins are called dysopsonins.93 
Human serum albumin (HSA) is the main protein of the dysopsonin family, accounting for more 
than 50% of the overall protein mass in blood. HSA is a natural carrier of cations (Ca2+, K+, 
Na+), hormones, bilirubin, fatty acids and small hydrophobic drugs. Due to its very high 
concentration in both serum and plasma, an initial binding of HSA is expected on any 
nanoparticle, which may be subsequently replaced by proteins exhibiting higher affinities, 
according to the Vroman effect.95 Alongside HSA, other dysopsonins such as α-1-acid 
glycoprotein, afamin, α-2-macroglobulin all belong to the albumin family, they contribute to 
binding of nanoparticles and improve their retention times, thus favoring the blood availability 
of the bound nanoparticles. HSA-drug conjugates favor the drug bioavailability, in the same 
way as nanoparticle-drug conjugates. HSA functions as autonomous nanocarrier in 
commercially available formulations, for example in Abraxane®, an HSA-paclitaxel conjugate 
for the handling of metastatic breast and lung cancers.96  
The presence of certain proteins in the corona of nanoparticles has shown interesting effects 
on the nanoparticle properties / stability / therapeutic efficacy. The prolonged residence of 
HSA, as well as ApoA-IV, ApoC-III, or clusterin in the corona of nanoparticles, showed to inhibit 
nanoparticle cell uptake.97-99 On the other hand, the presence of vitronectin, ApoA-I, ApoA-II, 
ApoB-100, ApoC-II, on the protein corona was correlated to an enhanced uptake of 
nanoparticles through receptor-mediated endocytosis.97, 100-103 
The presence of one or several layers of coated proteins may shield the active targeting 
moieties on the nanoparticle’s surface by steric crowding,104-108 except for monoclonal 
antibodies, that retain their specificity and binding affinities towards their antigen, even in 
physiological high concentrations of protein.109 Coincidentally, new protein-cell interactions 
may generate corona-directed targeting. The presence of apolipoproteins (ApoA-I, ApoB-100) 
or retinol-binding protein improved targeting of liver Kupffer cells, for the treatment of 
hyperlipidemia or other cholesterol-related diseases.110-112 The presence of ApoE was in turn 
correlated with the ability of nanoparticles to cross the blood-brain barrier (BBB), for improved 
brain targeting,113, 114 while vitronectin was promoting association with α2β3 integrin found on 
cell surfaces, due to the interaction with the tripeptide arginine – glycine – aspartic acid (RGD) 
motif, found enriched in the protein.115 
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The formation of a protein corona may mitigate the cytotoxicity of nanoparticles, by preventing 
generation of reactive oxygen species (ROS),116, 117 or by neutralizing positively charged 
surfaces of nanoparticles.118, 119 However, other reports show new cytotoxic effects arising from 
the loss of the protein’s native structure after binding to the nanoparticle’s surface.120-123  
The presence of a layer of coating proteins has a curbing effect on the release kinetics of 
molecular cargo by nanocarriers, due to sterics that limit free diffusion through the protein 
layers.124 This effect may counteract boost release in some instances, to give a more desired 
sustained kinetics and improve the nanocarrier’s efficacy.125 
The colloidal stability and nanoparticle conformation may also be affected by its protein corona. 
The most striking example being that of lipoplexes, that are liposomal nanocarriers complexed 
to nucleic acids for gene transfection. When in contact with proteins, lipoplexes are able to 
intercalate proteins inside a multilamellar structure, thereby increasing their size and 
consequently altering the transfection efficiency,126 while in specific cases the altered lipoplex 
conformation improved the DNA loading capacity.127 In other reports, the bridging of 
nanoparticles due to protein intercalation after incubation in plasma or serum caused 
nanoparticle aggregation and loss of the colloidal stability of nanoparticles.128-131  
 
1.2.2.  Physics of Competitive Protein Binding to Nanoparticles 
Due to the heterogeneity of blood protein samples, the outcomes of a systematic study about 
thermodynamics and kinetics of protein corona formation are affected by a wide number of 
parameters, such as incubation time, protein concentration, temperature, pH and ionic 
strength. A combination of hydrophobic interactions (van der Waals) with apolar segments of 
proteins and coulombic interactions with charged residues on the polypeptide chains is the 
driving force that regulates the thermodynamics of protein binding onto nanoparticles, in a 
spontaneous attempt to reduce the nanoparticle’s surface energy.132-138 Many physicochemical 
characteristics of nanoparticles show a direct influence on the protein corona composition, 
surface charge and hydrophobicity being the two main factors. Nanoparticle size, roughness, 
and density are also concurring in defining the protein affinity towards nanoparticles, as seen 




Fig. 1.8 Main physicochemical properties of nanoparticles that influence the protein binding. 
Reproduced with permission from Nel et al., copyright 2009 MacMillan Publishers Limited. 85 
The size of a nanoparticle is defining its curvature angle. It was shown that the bigger the 
nanoparticle, the smaller the curvature angle, and the docking of a protein onto a flat surface 
is a more favored process.139 In this case, the binding of the first layer of proteins, especially 
onto big, hydrophobic nanoparticles, may result in protein unfolding, generally by flattening of 
the protein and loss of native structure.140  The roughness of a nanoparticle is also associated 
with an increase in protein binding, due to localized pitfalls in surface energy that promote 
protein nucleation.141 
All of the aforementioned trends in protein binding are useful during the initial stage of 
nanoparticle design for blood compatibility. However, these trends are not able to fully predict 
the protein corona composition, due to the broad spectrum of variables involved in the process. 
A few reports approached the issue of modelling thermodynamics of competitive protein 
absorption processes,142-146 to predict the protein corona. In presence of multiple different 
proteins, the process can be formalized into a multicomponent Langmuir absorption isotherm, 
provided that the protein association is a reversible process. Starting from a single component 
isotherm, for the modeling of a reversible single protein binding, we get Θ = 𝐾𝐾𝑏𝑏[𝑃𝑃]
1+𝐾𝐾𝑏𝑏[𝑃𝑃], where Θ 
is the fraction of bound sites on a nanoparticle occupied by protein P, with a concentration [P] 
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and a binding constant Kb. A two-component Langmuir isotherm may be expressed as 
𝛩𝛩𝑖𝑖�[𝑃𝑃𝑖𝑖], �𝑃𝑃𝑗𝑗�� = 𝐾𝐾𝑏𝑏,𝑖𝑖[𝑃𝑃𝑖𝑖]1+𝐾𝐾𝑏𝑏,𝑖𝑖[𝑃𝑃𝑖𝑖]+𝐾𝐾𝑏𝑏,𝑗𝑗�𝑃𝑃𝑗𝑗�, provided that no protein-protein interactions are involved in the 
binding process.147 Knowing the Kb values, measured by isothermal titration calorimetry (ITC) 
from single protein absorption studies, the two-component isotherm is still solved analytically 
by a quadratic equation. In more complex environments such as human plasma or serum, due 
to the great heterogeneity of the protein samples, such an equation may not be solved 
analytically. 
The Langmuir isotherm may also be correlated with the kinetic constants of protein binding, 
which show Kb = kon / koff, where kon is the association constant for the single protein and koff 
the dissociation constant. The two kinetic parameters usually differ, they range from 10-3 s-1 to 
104 s-1 for the binding onto nanoparticles.90 These values relate to a competitive binding setting, 
where many proteins attach and detach on a single surface. As shown by Vroman in 1986, the 
association of proteins onto surfaces is a dynamic process, in which a preliminary assembly 
may arise from the binding of the most abundant proteins in solution, to be gradually replaced 
by proteins with higher affinities and lower concentrations in the medium (Vroman effect).95  
Due to multi-component competitive binding, a prediction for the composition of the protein 
coronae in serum or plasma cannot be assessed via modeling of the nanoparticle binding. 
Thus, for a full quantitative profiling of the protein coronae, in vitro protein binding studies are 
necessary. After incubation in protein - rich media (human plasma or serum, cell culture 
medium, fetal bovine serum, mouse plasma or serum), the isolation of the protein corona 
requires several consecutive washing steps to eliminate residual unbound proteins. The 
separation of the unbound proteins affords usually via centrifugation, size exclusion 
chromatography,148 or asymmetrical flow-field flow fractionation.149 The characterization of the 
isolated protein corona samples usually involves the use of proteomics (SDS-PAGE, LC-MS) 
for the quantitative profiling of proteins.102 Structural information about the nanoparticle-protein 
corona complex may be obtained by dynamic light scattering (DLS) measurements even 
without the need of isolating the samples from the incubation medium.150, 151 For a 
thermodynamic assessment of the protein binding process, ITC is regarded as the standard 
methodology.56, 150, 152 Other methodologies include hyperspectral imaging,153 fluorescence 
correlation spectroscopy,154 or UV-VIS spectroscopy. A combination of these methodologies 





1.2.3.  Protein Corona Around Polymeric Nanoparticles 
The research involved in the understanding of nanoparticle interactions with proteins were first 
implemented for the assessment of the nanotoxicity of hard, inorganic nanoparticles arising 
from industrial applications and their unwanted interaction with biological tissues.158-163 The 
involvement of researchers for the understanding of protein interactions with nanoparticles that 
were specifically designed for their use in medicine was the next step. In the last ten years, an 
increasing number of studies were performed to understand the interactions of polymeric or 
lipid-based nanocarriers with proteins in physiological conditions. In these studies, 
nanoparticles were incubated in different biological media, mostly human plasma or serum. 
The two media differ for their protein composition, as serum is thermally inactivated plasma, 
which leads to fibrinogen polymerization to depleted insoluble fibrin by spontaneous clotting. 
Human plasma is the full proteinaceous component of blood, and it has added bivalent cations 
such as Ca2+ to stabilize fibrinogen in solution, which in turn inactivates at the same time the 
complement system. Therefore, depending on the main focus of the studies, a careful choice 
of the used biological medium is required, especially for the investigation of fibrinogen binding 
(plasma) or complement activation (serum). This said, for a full protein corona profiling, both 
media should be investigated in parallel experiments, when applicable.164 The predictions for 
protein associations based on the nanoparticle’s polymer chemistry shows distinct tendencies. 
While hydrophilic nanoparticles will bind dysopsonins belonging to the albumin family, in turn 
hydrophobic nanoparticles will be involved in apolipoprotein binding. A definite number of 
proteins were found associated to polymeric nanoparticles, especially complement C3, IgG, 





Nanoparticle* Size (nm) Main components of protein corona* Ref. 
PLA 161 IgG, ApoE, HSA, antithrombin, complement C3, ApoJ 164, 
165 




PLA-PVP 226-248 Complement C3, C4, C5, C8, C9 166 
PLGA 227 ApoE, histidine-rich glycoprotein, vitronectin, kininogen-1, β-2-
glycoprotein 1, coagulation factor V, serum amyloid A-4 protein 
167 
PLGA-PEG 173 ApoE, IgG, fibrinogen, ApoA-IV, ApoA-I 165 
PCL-PEG 164 IgG, ApoC-II, HSA, fibrinogen, ApoA-I, ApoC-III, Ig light chains 165 
PCL-DEX 136-188 IgG, ApoE, HSA, fibrinogen, ApoA-IV, ApoA-I, complement C3 168 
PS-PEG 118 Clusterin 98 
PS-PEEP 120 Clusterin 98 
PS-Glu 725-853 Complement C3, ApoA-I, ApoA-IV, HSA, ApoC-I, ApoC-III, ApoE 169 
PS-Gal 747-852 Complement C3, ApoA-I, ApoA-IV, HSA, ApoC-I, ApoC-III, ApoE 169 
PNIPAM-BAM 70-700 ApoA-II, ApoE, HSA, ApoA-IV, ApoA-I, ApoB-100 56, 135, 
170 
dPG-PNIPAM 127 HSA 171 
dPG 115 HSA 171 
dPG-NH2 163 HSA 171 
CMS 18 HSA 171 
Mannan 170 ApoE, HSA, ApoA-I, ApoB-100 172 
PIBCA-DEX 152-297 Fibrinogen, ApoA-I, complement C3 173 
PIBCA-DEX-
Hep 
186 IgG, fibrinogen, complement C3 173 
PIBCA-DEX-
SO3- 
274 IgG, fibrinogen, complement C3 173 
PIBCA-Hep 93 IgG, fibrinogen 173 
PHDCA, 
PEG-PHDCA  
165-171 ApoA-II, IgG, ApoA-I, ApoA-IV, ApoJ, ApoC-II, ApoC-III, ApoE 174 
HES capsules 200-275 ApoA-I 150 
HES particles 165 ApoJ, fibulin-1 107 
HES-PEG 166 ApoA-I, complement C1q, ApoJ 107 
HES-PEG-
Man 
168-176 ApoJ, fibulin-1 107 




62 Complement C4b, ApoB-100, fibronectin, vitronectin, clusterin, 
ApoA-IV, gelsolin, ApoE 
175 
 
Table 1.1 List of main components of protein corona around polymeric nanoparticles. 
Reproduced with modifications from Miceli et al., copyright 2017 Royal Society of Chemistry. 
176 *PLA = poly(lactic acid); PLGA = poly(lactic-co-glycolic acid); PEG = poly(ethylene glycol); PVP = 
poly(vinylpyrrolidone); PCL = poly(e-caprolactone); DEX = dextran;  PS = polystyrene; PEEP = poly(ethyl ethylene phosphate); 
Glu = glucose; Gal = galactose; PNIPAM-BAM = poly(N-isopropylacrylamide-co-tert-butylacrylamide); dPG = dendritic 
polyglycerol;   CMS = core multi-shell nanocarrier; PIBCA = poly(isobutylcyanoacrylate); Hep = heparin; PHDCA =  
poly(hexadecylcyanoacrylate); HES = hydroxyethyl starch; Man = mannose, PMA = poly(methacrylic acid). Apo = 
apolipoprotein; Ig = immunoglobulin; HSA = human serum albumin.  
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By comparing the behavior with blood proteins of inorganic nanoparticles, polymeric 
nanoparticles seem to bind a less diverse group of proteins, supposedly due to their soft 
nature. The binding of IgG and complement C3 was found in many instances, while these 
proteins are opsonins, their impact on the clearance of the bound nanoparticles cannot be 
understood without analyzing the interactions with macrophages, as a follow up study. It is 
known that an immune reaction may be initiated only when a substantial amount of opsonins 
were depleted from human plasma and bound to the nanoparticles.177  
Another common feature of protein corona of polymeric nanoparticles is the binding of 
apolipoproteins, such as ApoA-I, ApoB-100, ApoE, ApoA-IV, ApoC-II, ApoC-III, among others. 
The binding of apolipoproteins is ubiquitous in hydrophobic nanoparticles, and according to 
the ApoA-I / ApoB-100 ratio found in the corona, a switch from high density lipoprotein (HDL) 
to low density lipoprotein (LDL) can occur.170 The values of lipoprotein concentration in blood 
are indicative of cholesterol-related diseases, and the presence of nanoparticles inside these 
lipoproteins may target the lipid metabolic processes and act as therapeutics. As previously 
discussed, ApoE in the corona may act as vector for the targeting of nanoparticles towards the 
brain,113, 114 while other apolipoproteins interact with the nanoparticle’s ability to target and / or 
penetrate cellular compartments.97-103 
pNIPAM copolymer nanogels showed a protein corona that was dependent on the 
copolymerization degree with N-tert-butyl acrylamide (BAM). The presence of the hydrophobic 
BAM increased the apolipoprotein binding, towards full lipoprotein (HDL) formation for 
nanogels having a 1:1 pNIPAM / BAM ratio. By increasing the hydrophilicity of the nanogels 
towards a 65:35 pNIPAM / BAM ratio, no lipoproteins were residing anymore in the corona.170 
A further discussion on the protein corona of pNIPAM-based nanogels is provided in Sections 
3.1-3.2 of this thesis. 
Overall, the binding of proteins onto nanoparticles is a complex interplay of multiple 
macromolecular actors, to generate heterogeneous supramolecular structures, that drastically 
alter the way in which the underlying nanoparticle is perceived, when interacting with biological 
tissues. The efficacy of therapeutic nanoparticles cannot be investigated without considering 
their interactions with proteins in a physiological environment, which may also help reducing 
harmful and failing in vivo tests. The protein corona itself may impair new improved 
characteristics to the nanoparticle, for a better bioavailability, reduced toxicity, improved 
release characteristics, or an improved targeting towards diseased tissues. The pre-coating 
with specific proteins before the intravenous administrations of nanoparticles may partially 
direct the structure of the protein corona in vivo, by delaying the Vroman effect, for an improved 




2.  Motivation and Objectives 
This work addresses the need for an improved design and performance of stimuli-responsive 
nanogels as macromolecular drug carriers in the framework of cancer therapy. The clinical 
target applications of nanogels require the optimization of the features of next generation drug 
carriers, obtained from a narrow range of starting materials, for an improved target selectivity 
and in situ drug delivery. pNIPAM-based nanoparticles show a wide range of applications for 
the fabrication of thermoresponsive devices, their application in medicine is of strong interest, 
due to its LCST close to the human body temperature. However, conventional pNIPAM 
nanoparticles exhibit LCST-dependent interchain aggregation in the micrometer range. The 
incorporation of dPG as nanogel component gives colloidally stable nanogels even above the 
pNIPAM LCST.71 Thermoresponsive, dendritic dPG-pNIPAM nanogels function as 
biocompatible drug delivery agents and the screening of different synthetic strategies for their 
optimization will be investigated in Section 3. The combination of innovative materials 
(dendritic or linear polymers), together with implementing different three-dimensional 
architectures into nanogels is the main paradigm of this thesis. In this way, new strategies will 
be used for the synthesis of stimuli-responsive nanogels, which allow an improved 
performance for drug loading and sustained release, and at the same time provide safe 
interaction with blood proteins, as shown in Fig. 2. 
 
Fig. 2. Main research topics involved in this doctoral thesis work. The interactions between 
stimuli-responsive nanogels and chemotherapy drugs, together with their interplay with serum 
proteins are crucial factors involved in the design of successful new generation nanogels for 
anticancer therapy. 
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The ability of dPG to inhibit the unspecific binding of proteins in physiological conditions is a 
fundamental part of the studies conducted in this thesis, as shown in Sections 3.1 – 3.2. The 
resulting findings will disclose information regarding the interactions at the bio-nano interface, 
which can lead to a new biological identity of the nanogels by formation of a protein corona. 
As a consequence, the performances of nanogels as drug carriers will be affected. Thus, the 
studies in this thesis are needed to assess these implications, to give a better understanding 
on the strong impact of the protein corona on the nanogel’s morphology and function.  
Semi-interpenetration is a useful way to obtain multicompartimental, dual-responsive 
nanogels, without perturbing the ability of dPG-pNIPAM nanogels to respond to thermal stimuli. 
The synthesis of responsive nanogels and the investigation of release kinetics of encapsulated 
drugs poses the fundaments for the framework of the research in this thesis and the related 
published articles. The optimal tuning of binding affinities towards therapeutic molecules of 
interest, as well as the responsive modalities of the nanogels to respond to changes in the 
surrounding environment will be explored with a screening of synthetic conditions and different 
polymer ratios. In this way, semi-interpenetrated nanogels are obtained, to achieve pH-
responsive networks within the thermoresponsive nanogel scaffolds, for the optimal binding 
and sustained release of therapeutic proteins (Section 3.3), as well as small drugs (Section 
3.5). 
The use of dendritic components is investigated in detail, as they can be implemented in 
combination with linear polymers, and function as multifunctional agents, in order to tune the 
reversible binding of therapeutic moieties. The effects of introducing a Newkome-type dendron 
as dendritic component in nanogels will be thoroughly discussed in Sections 3.3 - 3.4. In this 
way, this thesis attempts to fully assimilate all efforts reported for the screening of synthetic 
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3.1 Temperature dependency of elusive protein corona around 
thermoresponsive nanogels: key interactions above the lower critical solution 
temperature 
E. Miceli, B. Kuropka, C. Rosenauer, E. R. Osorio Blanco, L. Fechner, M. Kar, C. Weise, S. 
Morsbach, C. Freund, M. Calderón, manuscript submitted. 
 
 
Fig. 3.1 Thermoresponsive dPG-pNIPAM nanogels show temperature-dependent aggregation 
in serum. 
Author contribution: In this work, the author was responsible for the overall concept, the 
synthesis of thermoresponsive nanogels with screening of different dPG / thermoresponsive 
polymer ratios, as well as the generation of the protein corona samples and their isolation 
from human serum. The coordination with the research partners for the characterization of 
the protein corona was also done by the author, as well as the writing of the research report. 
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Abstract: In this work, a systematic study about protein corona characterization around 
thermoresponsive nanogels was carried out. Both dendritic polyglycerol (dPG) and poly(N-
isopropylacrylamide) (pNIPAM) are regarded as protein-resistant, biocompatible materials, 
thus we analyzed the elusive protein corona of thermoresponsive, pNIPAM- or poly (N-
isopropylmethacrylamide) (pNIPMAM)-based nanogels (NGs), crosslinked with dPG or N,N’-
methylenebisacrylamide (BIS). At 37 °C, we compare protein coronae of shrunken dPG-
pNIPAM NGs with swollen dPG-pNIPMAM NGs, to examine the influence of the NG solvation 
state on its protein binding. All dPG-containing NGs showed drastically lower protein 
absorption when compared with NGs without dPG. Apolipoprotein B-100 (ApoB) and serum 
albumin (HSA) were the main components of the protein coronae of NGs, alongside 
complement C3, C4, α-2-macroglobulin and transferrin. For dPG-pNIPAM NGs, a temperature-
dependent protein corona profile was observed. At 37 °C, when pNIPAM is hydrophobic, a 
pronounced aggregation was detected in serum, as well as a specific increase in 
immunoglobulin absorption in the low abundance regime. Overall, we found that small changes 
in the composition of protein corona around thermoresponsive nanogels may affect the NG’s 
colloidal stability and in vivo biocompatibility. Thus, similar studies are encouraged for other 
nanoparticle-based systems, to understand their propensity to bind proteins on their surface 
and preview their unspecific association with other components in tissues. The corona-
dependent aggregation of dPG-pNIPAM NGs at 37 °C may be exploited for enhanced localized 
toxicity. dPG-PNIPMAM NGs are hydrophilic at 37 °C and show safe profiles in serum for their 
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An intravenous administration of nanoparticles used for drug delivery faces the hurdle of the 
unspecific binding of proteins, to form a so-called protein corona. Such a supramolecular 
structure may induce unpredictable protein-cell associations, that influence the nanoparticle’s 
biodistribution profile, leading to changes in therapeutic efficacy and overall to a new biological 
identity. The use of antifouling polymers in nanoparticle synthesis helps decreasing unspecific 
protein absorption, however not quantitatively. While both dendritic polyglycerol (dPG) and 
poly(N-isopropylacrylamide) (pNIPAM) are regarded as protein-resistant, biocompatible 
materials, we analyzed the elusive protein corona of thermoresponsive, pNIPAM- or poly (N-
isopropylmethacrylamide) (pNIPMAM)-based nanogels (NGs), crosslinked with dPG or N,N’-
methylenebisacrylamide (BIS). pNIPAM and pNIPMAM exhibit sharp, reversible phase 
transitions at 33 °C and 46 °C, respectively, due to entropy-driven interchain aggregation. At 
37 °C, we compare protein coronae of shrunken dPG-pNIPAM NGs with swollen dPG-
pNIPMAM NGs, to examine the influence of the NG solvation state on its protein binding. All 
dPG-containing NGs showed drastically lower protein absorption in comparison with BIS-
crosslinked NGs. Traces of protein corona detected after 1 h incubation in human serum at 
either 25 °C or 37 °C were characterized by quantitative proteomics. Apolipoprotein B-100 
(ApoB) and serum albumin (HSA) were the main components of the protein coronae of NGs, 
alongside complement C3, C4, α-2-macroglobulin and transferrin. For dPG-pNIPAM NGs, a 
temperature-dependent protein corona profile was observed. At 37 °C, when pNIPAM is 
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hydrophobic, a pronounced aggregation was detected in serum, as well as a specific increase 
in immunoglobulin absorption in the low abundance regime. Overall, we found that small 
changes in the composition of protein corona around thermoresponsive nanogels may affect 
the NG’s colloidal stability and in vivo biocompatibility. A corona-dependent aggregation of 
NGs may be exploited for enhanced localized toxicity. The small changes in protein corona 
composition arose from the NG solvation state, regulated by the choice of thermoresponsive 
polymer as well as the system temperature. dPG-pNIPMAM NGs are hydrophilic at 37 °C and 
show safe profiles in serum and a dysopsonin-rich protein corona. 
 
Introduction 
Nanogels (NGs) are nanosized, crosslinked polymers that absorb large quantities of water. 
Stimuli-responsive NGs may be obtained by employing “smart” materials, whose properties 
can be regulated by applying changes in the environmental conditions. Physical stimuli such 
as changes in temperature, pH, light, enzyme or disulfide concentrations may be used to 
control the properties of NGs. [1] Poly(N-isopropylacrylamide) (pNIPAM) and poly(N-
isopropylmethacrylamide) (pNIPMAM) polymers exhibit temperature-dependent solubilities, as 
they show a coil-to-globule transition around their lower critical solution temperature (LCST). 
Such polymers allow the synthesis of NGs that exhibit reversible shrinking/swelling around the 
LCST (33 °C and 46 °C, respectively for pNIPAM and pNIPMAM). [2, 3] The use of pNIPAM 
as a thermoresponsive polymer is widespread and has been thoroughly researched in the last 
24 years as the gold standard for thermoresponsive NGs. [4] Its LCST of 33 °C, close to the 
temperature of the human body, together with low unspecific plasma protein absorption [5], no 
hemolytic activity, and antithrombotic behavior, [6] make pNIPAM a polymer of choice for 
biomedical applications. [1] In order to overcome pNIPAM aggregation above its LCST, our 
group reported the synthesis of thermoresponsive pNIPAM NGs, with the aid of dendritic 
polyglycerol (dPG) as macromolecular crosslinker. dPG-pNIPAM NGs are colloidally stable 
above the pNIPAM LCST since dPG increases the hydrophilicity of the NG to counterbalance 
pNIPAM interparticle aggregation. [7] The use of dPG has proven beneficial as antifouling 
polymer / nanoparticle (NP). It showed no complement activation as well as no induced 
cytotoxicity and very low affinity for protein binding. [8] dPG belongs to a class of antifouling 
materials, such as poly(ethylene glycol) (PEG), poly(ethyl ethylene phosphate) (PEEP), [9] or 
zwitterionic polymers, [10] that have been demonstrated to improve NP biocompatibility, 
however, many times they show traces of protein corona. The binding of proteins on the 
surface of NPs is an unavoidable phenomenon, when nanoparticles are immersed in bodily 
fluids, such as blood plasma or serum. [11] As a result, a supramolecular protein corona alters 
the therapeutic properties of NPs by introducing new protein - protein, or protein - cell 
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interactions. [12-14] Such new interactions may benefit the host NP in some instances, 
however, usually they reduce NP potency [12] as well as confer toxicity due to opsonization 
and accumulation in the mononuclear phagocyte system (MPS). [15] It is therefore of 
fundamental importance to characterize the protein corona around NPs, to gain an 
understanding of NP blood compatibility and in vivo therapeutic efficacy. [16] 
The main driving forces regulating NP - protein binding are hydrophobic (van der Waals) and 
coulombic interactions. Other NP properties (size, roughness, density) are directly affecting 
the protein binding, as shown by several experimental and computational reports. [16-18] As 
a result, hydrophobic and charged NPs are more prone to protein binding, and by regulating 
these two factors one could steer the protein corona towards a more desired composition. 
While it is not possible to maintain a specific composition of the protein corona due to constant 
exchange of bound proteins (Vroman effect), [17] another strategy that was proven beneficial 
to partially control the corona composition is the pre-coating of NPs with the desired proteins, 
prior to their incubation in biological fluids. [18]  
While there are no reports for the protein corona of pNIPMAM, previous reports for pNIPAM 
NGs show little to no absorption of proteins. [5, 12] By increasing the hydrophobicity of 
pNIPAM, through copolymerization with tert-butylacrylamide, an increase in apolipoproteins 
and full lipoproteins (mostly HDL) was reported in the corona below the LCST. [19, 20] Overall, 
these studies lack, however, the understanding of the role of pNIPAM thermoresponsiveness 
on its protein absorption behavior. In fact, for thermoresponsive poly(2-isopropyl-2-oxazoline) 
NPs, studies show a temperature dependency of the protein corona, and a reversible 
aggregation of NPs when incubated in human serum above their LCST. [21]  
This study aims to distinguish between protein coronae of dPG-pNIPAM NGs in the two 
different solvation states of pNIPAM (swollen at 25 °C, shrunken at 37 °C), as well as 
understanding the influence of the antifouling dPG on the protein corona. Furthermore, we 
compare protein coronae of shrunken dPG-pNIPAM and swollen dPG-pNIPMAM NGs at 
37 °C, to gain insight into the role of the NGs’ solvation state. Structural data was provided by 
dynamic light scattering (DLS) in concentrated human serum, which could determine a size 
increase of the species in situ, without having to isolate the sample from the medium. Liquid 
chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) in 
conjunction with 18O-labeling was performed to achieve a quantitative profile of the 






Materials and Methods 
dPG-pNIPAM NGs were synthesized by one-pot precipitation polymerization according to 
procedures already published by our group. [7] The same procedure was adapted for the 
synthesis of dPG-pNIPMAM NGs by using potassium persulfate as initiator and discarding 
tetramethylethylenediamine as accelerator. Different feed ratios of dPG were used to obtain 
NGs with increasingly high dPG amounts. The synthesis of pNIPAM/BIS and pNIPMAM/BIS 
NGs was performed by similar procedures previously reported in the literature. [4] 
The incubation of NGs in human serum was performed by mixing a 20 mg/mL NG solution with 
an approximately 9-fold excess in volume of human serum, provided to keep the NG surface 
density constant at 8 m2 / L serum. All samples were incubated for 1 h, either at 25 °C or 37 
°C. 
The isolation of the protein corona was performed by ultrafiltration (molecular weight cutoff 
MWCO = 1 MDa) by washing with excess PBS, which was previously kept at a constant 25 °C 
or 37 °C, according to the previous incubation temperature in serum. Short centrifugation steps 
of maximum 10 s were employed to prevent sample cooling from 37 °C. 
In order to quantify protein amount, Bradford assay was used: 100 mg Coomassie Brilliant 
Blue G250 was dissolved in 50 mL of Ethanol, 100 mL of concentrated phosphoric acid was 
added, and the volume was adjusted to 200 mL with MilliQ water. The reagent was mixed in a 
1:1 ratio to the protein sample, absorbance values were recorded at 595 nm. 
The obtained NG-protein corona samples were filtered through a 450 nm syringe filter and 
proteins were eluted with SDS sample buffer at 95 °C for 10 min. Subsequently, the 
corresponding samples were separated by SDS-PAGE (Tris-glycine gradient gel, 10%, Bio-
Rad). The run was stopped after 2 min so that all proteins were retained in a single gel band. 
Gel bands of corresponding samples were cut, reduced with 100 mM dithiothreitol (DTT) and 
alkylated with 55 mM iodoacetamide. In-gel protein digestion and 16O/18O-labeling was 
performed as described. [22, 23] In brief, corresponding samples were incubated overnight at 
37 °C with 50 ng trypsin (sequencing grade modified, Promega) in 25 μL of 50 mM ammonium 
bicarbonate in the presence of heavy water (Campro Scientific GmbH, 97% 18O) and regular 
16O-water, respectively. To prevent oxygen back-exchange by residual trypsin activity, 
samples were heated at 95 °C for 20 min. After cooling down, 50 μL of 0.5% TFA in acetonitrile 
was added to decrease the pH of the sample from ~8 to ~2. Afterwards, corresponding heavy- 
and light-isotope samples were combined and peptides were dried under vacuum. Peptides 
were reconstituted in 15 μL of 0.1% (v/v) TFA, 5% (v/v) acetonitrile and 6.5 µL were analyzed 
by a reversed-phase capillary nano liquid chromatography system (Ultimate 3000, Thermo 
Scientific) connected to an Orbitrap Velos mass spectrometer (Thermo Scientific). The LC 
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system was coupled to the mass spectrometer via a nanospray flex ion source equipped with 
a stainless-steel emitter (Thermo Scientific). Samples were injected and concentrated on a 
trap column (PepMap100 C18, 3 μm, 100 Å, 75 μm i.d. × 2 cm, Thermo Scientific) equilibrated 
with 0.05% TFA, 2% acetonitrile in water. After switching the trap column inline, LC separations 
were performed on a capillary column (Acclaim PepMap100 C18, 2 μm, 100 Å, 75 μm i.d. × 
25 cm, Thermo Scientific) at an eluent flow rate of 300 nL/min using a linear gradient of 3–50% 
B in 50 min. Mobile phase A contained 0.1% formic acid in water, and mobile phase B 
contained 0.1% formic acid in acetonitrile. Mass spectra were acquired in a data-dependent 
mode utilizing a single MS survey scan with a resolution of 60,000 in the Orbitrap, and MS/MS 
scans of the 20 most intense precursor ions in the linear trap quadrupole. The MS survey range 
was m/z 350-1500. The dynamic exclusion time (for precursor ions) was set to 60 s and 
automatic gain control was set to 1 × 106 and 5.000 for Orbitrap-MS and LTQ-MS/MS scans, 
respectively. 
Identification and quantification of 16O/18O-labeled samples was performed using the Mascot 
Distiller Quantitation Toolbox (version 2.6.1.0, Matrix Science). Data were searched against 
the SwissProt human protein database (May 2017). A maximum of two missed cleavages was 
allowed and the mass tolerance of precursor and sequence ions was set to 10 ppm and 0.35 
Da, respectively. Cysteine carbamidomethylation was set as a fixed modification. Methionine 
oxidation, acetylation (protein N-terminus), and C-terminal 18O1- and 18O2-isotope labeling were 
used as variable modifications. A significance threshold of 0.05 was used based on decoy 
database searches. For quantification at protein level, a minimum of two quantified peptides 
was set as a threshold. Relative protein ratios were calculated from the intensity-weighted 
average of all peptide ratios. Known contaminants (e.g. keratins) were removed from the 
protein output tables. Normalization of protein ratios was performed using the median ratio of 
all proteins. Only proteins that were identified and quantified in all three replicates were 
considered.  
All light scattering experiments were performed on a commercially available instrument from 
ALV GmbH (Langen, Germany) consisting of an electronically controlled goniometer and an 
ALV-5000 multiple tau full-digital correlator with 320 channels (resolution of 10−7 s ≤ 𝑡𝑡 ≤103 s). A HeNe laser with a wavelength of 632.8 nm and an output power of 25 mW (JDS 
Uniphase, Milpitas, USA, Type 1145P) was utilized as the light source. For each sample 
containing a mixture of serum and NPs 1 mL of concentrated serum was filtered through Millex 
GS filters with a pore size of 220 nm (Merck Millipore, Billerica, USA) into dust-free quartz light 
scattering cuvettes (inner diameter 18 mm, Hellma, Müllheim), which were cleaned before with 
acetone in a Thurmont-apparatus. Afterwards, 25 µL of the corresponding NP suspension with 
a concentration of 1 w/w% were added. For reference measurements either pure serum (1 mL, 
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filtered with Millex GS 220 nm) or NPs in MilliQ water (25 µL NP suspension in 1 mL water, 
Millex GS 220 nm filtered) were used. All samples were incubated at either 25 °C or 37 °C for 
1 hour prior to the measurement.  
Data analysis was performed according to the procedure described by Rausch et al.[24] using 
exponential fits of pure serum and pure NP suspensions as a reference. The mixture of both 
was then fitted by the sum of the pure components and additionally formed species were 
described by an additional exponential term, giving the intensity contribution and decay rate of 
the found diffusing species. 
Results and discussion 
We synthesized NGs by one-pot precipitation polymerization of NIPAM or NIPMAM, by 
crosslinking with dPG-acrylate or N,N’-methylenebisacrylamide (BIS), according to procedures 
already published by our group and others. [4, 7] We obtained NGs with increasing dPG 
content, in the range 0 – 38 w/w%, by repeated polymerizations with increasing dPG amounts. 
A dPG content higher than 40 w/w% in the NGs led to the loss of thermoresponsiveness and 
was therefore not used in this study. The control NG samples without dPG were crosslinked 
with 4 mol% BIS. The resulting NGs were characterized via DLS and nuclear magnetic 
resonance (1H-NMR) spectroscopy, the resulting data is shown in Table S1, please refer to the 
Supporting Information. 
pNIPAM samples with up to 5% dPG show aggregation at 37 °C. A higher amount of dPG in 
the NGs led to colloidally stable particles, that shrunk at 37 °C, without undergoing interparticle 
aggregation. pNIPMAM samples in turn do not shrink below 46 °C, as shown from the 
characterization data in Table 1, and they are swollen at a physiological temperature of 37 °C. 
To form a protein corona, the NGs were incubated in human serum, for 1 h @ 37 °C, at a 
constant surface density of 8 m2 NG / L serum. The isolation of the protein corona - NG complex 
was performed via ultrafiltration (molecular weight cutoff MWCO = 1 MDa), and extensive 
washing with sodium phosphate buffer saline (PBS). All corona isolation steps were done at 
constant 37 °C or 25 °C, in case the samples were not colloidally stable at 37 °C. The protein 





Fig. 1 Protein corona quantification for pNIPAM- (left) and pNIPMAM-based (right) nanogels, 
measured via Bradford assay.  
The results showed that the protein absorption of control pNIPAM/BIS and pNIPMAM/BIS NGs 
was already low, as previously reported, with concentrations of 3 – 7 μg protein / m2 NG. For 
comparison, for the protein corona around hydroxyethylstarch (HES) nanocapsules a higher 
content of 320 – 470 μg / m2 was found. [25] Nevertheless, by introducing dPG as crosslinker, 
the amount of absorbed protein was further reduced 13-fold for pNIPAM and 10-fold for 
pNIPMAM, leaving only traces of protein absorbed by NGs.  
By comparing the two data sets in Fig. 1, we observe a moderately higher protein absorption 
of pNIPAM samples in comparison with pNIPMAM NGs. By increasing the concentration of the 
hydrophilic antifouling reagent dPG, the amount of protein in the corona was drastically 
reduced in compliance with the literature. [8] dPG-pNIPAM NGs showed a thermal 
dependency of the overall amount of absorbed protein, being higher at 37 °C, as expected for 
the increased hydrophobicity of pNIPAM, as previously reported. [6] pNIPAM/BIS and 5% 
dPG-pNIPAM NGs were not stable in water above the LCST (Table S1), thus they were only 
investigated in serum at 25 °C. 
While we expect a safe profile for the NG’s hemocompatibility with such low protein amounts, 
we proceeded by analyzing their behavior in human serum via DLS. In this way, no sample 
isolation was needed, to prevent the loss of structural information and include the elusive layers 
of protein corona (the so-called “soft” protein corona, that may not be isolated from the protein 
medium, as it may be too loosely bound to the NP). [25] The DLS analysis was performed 
according to the method described by Rausch et al., [24] by the differential analysis of the 
autocorrelation functions (ACFs) obtained by the single scattering components. First, the ACFs 
of the individual components (pure concentrated serum and pure NG solutions) were 
determined. After that the mixtures can be evaluated with the so-called “force fit”: a sum of the 
individual ACFs with variable intensity contributions. Should the force fit not be sufficient to 
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describe the data, a third “aggregate” term is added to fit the additionally formed species, which 
is larger than the individual components. This results in the expression 𝑔𝑔1,𝑆𝑆(𝑡𝑡) =
𝑎𝑎1,𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 exp �− 𝑡𝑡𝜏𝜏1,𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆� + 𝑎𝑎2,𝑁𝑁𝑁𝑁 exp �− 𝑡𝑡𝜏𝜏2,𝑁𝑁𝑁𝑁� + 𝑎𝑎3,𝐴𝐴𝐴𝐴𝐴𝐴 exp �− 𝑡𝑡𝜏𝜏3,𝐴𝐴𝐴𝐴𝐴𝐴�  with the amplitudes 𝑎𝑎𝑖𝑖 and 
the decay times 𝜏𝜏𝑖𝑖 = 1𝑞𝑞2𝐷𝐷𝑖𝑖 , where 𝑞𝑞 = 4𝜋𝜋𝜋𝜋𝜆𝜆0 𝑠𝑠𝑠𝑠𝑠𝑠 �𝜃𝜃2� is the scattering vector and 𝐷𝐷𝑖𝑖 the single 
component’s Brownian diffusion coefficient. Following this method, the size increase of a 
nanomaterial due to protein absorption (if the increase is significant) or aggregation 
phenomena can be monitored. The ACFs of the evaluated NGs together with the 
corresponding fits are shown in Fig. 2 and the resulting aggregate sizes and intensity 
































Fig. 2 Autocorrelation functions (ACFs) of thermoresponsive nanogels in concentrated human 
serum for an exemplary scattering angle of 30°. Upper graphs show the obtained data points 
(open circles) together with a force fit (red line) and a fit containing an additional aggregate 
term (blue line) where applicable. Lower graphs show the residuals between fits and data 
points and detected size increases (data cannot be described by the force fit) are highlighted 
with yellow circles.  
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Table 1. Summary of the multi-angle dynamic light scattering data acquired in human serum 
for thermoresponsive nanogels. 
Sample Particle size in 
H2O (d.nm) 




pNIPAM / BIS 25 °C 250 ± 26 > 1000 10 
33% dPG-pNIPAM 25 °C 276 ± 28 - - 
33% dPG-pNIPAM 37 °C 220 ± 22 > 1000 78 
pNIPMAM / BIS 37 °C 190 ± 20 834 ± 84 27 
33% dPG-pNIPMAM 37 °C 144 ± 14 374 ± 38 14 
 
All NGs in their hydrophilic state showed moderate aggregate formation with aggregate 
intensity fractions of less than 30%. The size of the formed aggregates, however, was quite 
large for the NGs without dPG and a result of NG clustering. The presence of dPG decreased 
the aggregate intensity fraction in both cases, going from 10% to 0% for pNIPAM at 25 °C, and 
from 27% to 14% for pNIPMAM at 37 °C with a significantly reduced aggregate size. In 
contrast, 33% dPG-pNIPAM NGs showed pronounced, temperature-dependent aggregation 
in serum at 37 °C, even though no aggregation could be detected at 25 °C. The hydrophobic 
transition of pNIPAM in serum led to interparticle aggregation, resulting in micrometer-sized 
particles. This finding may corroborate what was observed by Obst et al., where the NGs 
showed flocculation in DLS in water, after their incubation in human plasma. [12] The same 
behavior was observed for NPs based on thermoresponsive poly(2-isopropyl-2-oxazoline), 
showing aggregation only above the polymer’s LCST. [21] 
In order to characterize the elusive protein coronae obtained around pNIPAM and pNIPMAM 
NGs with varying crosslinkers (dPG or BIS) and temperatures (25°C or 37°C), we used 
quantitative proteomics. By utilizing the 16O/18O-labeling method we were able to quantify the 
relative changes in the protein coronae of four pairwise comparisons as highlighted in Table 
2. Protein coronae were isolated by incubation of the NGs with human serum for 1 h followed 
by extensive washing using a 450 nm syringe filter. Proteins were eluted from the NGs by 
boiling in SDS sample buffer and a short SDS-PAGE was performed for protein clean-up, so 
that all proteins were contained in a single gel band. Subsequently, proteins from pairwise 
comparisons were in-gel digested with trypsin in the presence of “light” water (H216O) or “heavy” 
water (H218O). Peptides were extracted from the gel and corresponding “heavy” and “light” 
peptide samples were pooled and analyzed by LC-ECI-MS/MS. Each experiment was done in 
triplicate and about 40 proteins were reproducibly identified and quantified in each experiment 
(Table S2-S5, Supporting Information). The majority of proteins showed isotopic heavy-to-light 
(H/L) ratios around 1 (1:1), indicating that these proteins are of equal abundance in both 
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conditions/samples. Proteins that show reproducible relative enrichment in the heavy form (H/L 
ratio > 1.5) or in the light form (H/L ratios < 0.66) indicate specific binding to the corresponding 
nanogels (Table 2).  
Table 2. Overview of the experimental settings for quantitative proteomics experiments and 
the number of proteins that were reproducibly identified and quantified (n=3) in the corona of 
thermoresponsive nanogels. 
 
Labeled light (16O) Labeled heavy (18O) # of proteins 
Experiment 1 33% dPG-PNIPAM (37°C) 33% dPG-PNIPMAM (37 °C)  34 
Experiment 2 33% dPG-PNIPAM (25°C) 33% dPG-PNIPAM (37°C) 35 
Experiment 3 33% dPG-PNIPAM (25°C)  PNIPAM/BIS (25 °C)  46 
Experiment 4 PNIPMAM/BIS (37°C) 33% dPG-PNIPMAM (37°C) 44 
 
Table 3 summarizes the results of experiment 1, in which the protein coronae of 33% dPG-
pNIPAM and 33% dPG-pNIPMAM were compared, both at 37 °C. Here, H/L ratios < 0.66 
indicates preferential binding to dPG-pNIPAM, while H/L ratios > 1.5 indicate preferential 
binding to dPG-pNIPMAM. Table 4 summarizes the results from experiment 2 in which the 
protein coronae of 33% dPG-pNIPAM were compared at 25°C (hydrophilic) and 37°C 
(hydrophobic). In this experiment, H/L ratios < 0.66 indicate preferential binding at 25°C, while 
H/L ratios > 1.5 indicate preferential binding at 37 °C. Whole datasets for experiments are 




Table 3. Excerpt from the proteomics analysis of protein coronae around 33 w/w% dPG-
pNIPAM (L) and 33 w/w% dPG-pNIPMAM nanogels (H) incubated in human serum for 1 h at 
37 °C. The top 10 most abundant proteins are ranked in order of their mean number of 
identified peptide sequences from three independent replicates. Below, proteins that show 
significant enrichment to 33 w/w% dPG-pNIPAM (mean H/L ratio < 0.66) and 33 w/w% dPG-
pNIPMAM (mean H/L ratio > 1.5) are shown. Mean H/L ratios indicate the mean 18O/16O ratios 
from three independent experiments. Mean H/L ratios with p-values ≤ 0.05 were considered 
significant.  
















Serum albumin ALBU_HUMAN 71.3 3415 56 1.63 0.012 
Apolipoprotein B-100 APOB_HUMAN 516.7 3861 49 0.26 0.003 
Complement C3  CO3_HUMAN 188.6 2322 46 1.08 0.217 
α-2-macroglobulin  A2MG_HUMAN 164.6 2160 42 0.63 0.010 
Serotransferrin  TRFE_HUMAN 79.3 1524 31 1.50 0.015 
Complement C4-A  CO4A_HUMAN 194.3 863 17 0.98 0.781 
α-1-antitrypsin  A1AT_HUMAN 46.9 668 16 1.11 0.239 
Complement C4-B  CO4B_HUMAN 194.2 859 16 1.00 0.980 
Haptoglobin  HPT_HUMAN 45.9 620 14 0.74 0.255 
Immunoglobulin 
heavy constant mu  IGHM_HUMAN 50.1 485 12 0.58 0.051 


















Apolipoprotein B-100 APOB_HUMAN 516.7 3861 49 0.26 0.003 
α-2-macroglobulin  A2MG_HUMAN 164.6 2160 42 0.63 0.010 
Serotransferrin TRFE_HUMAN 79.3 1524 31 1.50 0.015 
Serum albumin ALBU_HUMAN 71.3 3415 56 1.63 0.012 






Table 4. Excerpt from the proteomics analysis of protein coronae around 33 w/w% dPG-
pNIPAM nanogels incubated for 1 h at 25 °C (L) and 37 °C (H). The top 10 most abundant 
proteins are ranked in order of their mean number of identified peptide sequences from three 
independent replicates. Below, proteins that show significant enrichment to 33 w/w% dPG-
pNIPAM at 25 °C (mean H/L ratio < 0.66) and 37°C (mean H/L ratio > 1.5) are shown. Mean 
H/L ratios indicate the mean 18O/16O ratios from three independent experiments. Mean H/L 
ratios with p-values ≤ 0.05 were considered significant.  
















Apolipoprotein B-100 APOB_HUMAN 516.7 2703 63 1.43 0.154 
Serum albumin  ALBU_HUMAN 71.3 3443 62 0.93 0.304 
Complement C3  CO3_HUMAN 188.6 2406 51 1.03 0.100 
α-2-macroglobulin  A2MG_HUMAN 164.6 1947 43 1.10 0.378 
Serotransferrin  TRFE_HUMAN 79.3 1273 27 0.96 0.424 
Complement C4-B  CO4B_HUMAN 194.2 769 23 0.83 0.074 
Complement C4-A  CO4A_HUMAN 194.3 713 23 0.81 0.082 
α-1-antitrypsin  A1AT_HUMAN 46.9 703 16 0.96 0.147 
Immunoglobulin 
heavy constant mu  IGHM_HUMAN 50.1 491 14 1.24 0.202 
Haptoglobin  HPT_HUMAN 45.9 576 13 0.96 0.548 



















lambda-1 light chain 
IGL1_HUMAN 23.1 120 3 1.64 0.026 
 
For all samples in this study, Apolipoprotein B-100 (ApoB), dysopsonins (serum albumin, α-2-
macroglobulin, transferrin) and complement proteins (C3 and C4) were identified among the 
most abundant proteins in the samples, indicating that they were bound in the corona (Tables 
3, 4, and S2 – S5). ApoB is the main component of low density lipoprotein (LDL) and precursor 
of chylomicrons. In reported cases, the coating of NPs with ApoB was used to target 
lipoproteins for the treatment of hyperlipidemia. [26] Serum albumin is the most abundant 
serum protein. Together with α-2-macroglobulin and transferrin, their presence increases the 
bioavailability of NGs, by acting as dysopsonizing agents, prolonging the NG retention time in 
45 
 
blood. Complement proteins (mostly C3 and C4) and immunoglobulin mu were also found in a 
significant amount on the corona of all NGs. Complement proteins and immunoglobulins are 
part of the innate immune system. While their presence on the corona may signify an increased 
probability of immune response associated with opsonization, more information is still needed 
to assess this hypothesis. Previous reports revealed that the mere presence of complement 
proteins in the corona of Au NPs was not sufficient to activate the complement system, which 
required in turn a substantial depletion of complement proteins from blood plasma. [27] In this 
case, traces of proteins detected around NGs may not be enough to activate the complement 
system after all.  
When comparing the protein coronae of hydrophilic 33% dPG-pNIPMAM NGs and 
hydrophobic 33% dPG-pNIPAM NGs at 37 °C (experiment 1), we observe a significant 
enrichment of ApoB and α-2-macroglobulin (A2MG), to pNIPAM. Dysopsonins like serum 
albumin, transferrin and α-2-HS-glycoprotein on the other hand were enriched in the corona of 
pNIPMAM. Taken together, the increased hydrophilicity of pNIPMAM was able to shift the 
corona composition from an ApoB-rich corona, towards a dysopsonin-enriched one, as shown 










Fig. 3 Volcano plot of proteins identified in the coronae of 33 w/w% dPG-pNIPAM and 33 w/w% 
dPG-pNIPMAM nanogels after incubation with human serum for 1 h at 37 °C (left); Volcano 
plot of proteins identified in the coronae of 33 w/w% dPG-pNIPAM nanogels incubated for 1 h 
at 25 °C and 37 °C (right). Proteins were highlighted (red labels) if their mean H/L ratio (n=3) 
indicated more than 1.5-fold enrichment (mean H/L < 0.66 or mean H/L > 1.5). Mean H/L ratios 
with p-values ≤ 0.05 (-log(p) ≥ 1.3) were considered significant. 
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When comparing protein coronae of 33% dPG-pNIPAM NGs at 25 °C vs. 37 °C (experiment 
2), above and below the LCST of pNIPAM, we observe a specific, temperature-dependent 
enrichment of immunoglobulin lambda light chain (IGL1) at 37 °C, when the NGs are in their 
hydrophobic state. This finding was in compliance with what observed by Zhang et al., for 
pNIPAM NPs in human plasma. [6] The hydrophobic transition underwent by pNIPAM was 
followed by aggregation of NGs in serum, as seen from DLS measurements (Fig. 2). The same 
phenomenon was observed by Koshkina et al., for poly(2-isopropyl-2-oxazoline) NPs, when 
incubated in serum above their LCST. [21] This might imply that the intrinsic hydrophobic shift, 
caused by heating of thermoresponsive polymers above their LCST, may promote protein-NG 
intercalation in blood, thereby compromising the NG’s stability. Moreover, the observed NG 
aggregation can be correlated to the changes in protein corona composition in serum at 37 °C. 
A similar net enrichment of IgG in low abundances was responsible for polystyrene NP 
bridging, caused by IgG denaturation and resulting in NP aggregation. [18, 28]  
Further experiments were performed, to understand whether dPG had an impact not only on 
the amount of bound protein, but also on the composition of the protein corona. Proteomics 
analysis revealed that dPG in the NGs increased their affinity for apolipoproteins. By comparing 
the compositions of the coronae of 33% dPG-pNIPAM and pNIPAM/BIS at 25 °C, we observed 
an increased affinity of the dPG-containing nanogel towards ApoB and haptoglobin. The 
control sample pNIPAM/BIS showed enrichment of several dysopsonins such as plasminogen, 
transferrin, and β-2-glycoprotein. Nevertheless, as accounted in Fig. 1, the overall amount of 
proteins on the coronae of pNIPAM/BIS was significantly higher. A similar comparison between 
33% dPG-pNIPMAM and pNIPMAM/BIS NGs at 37 °C found a net enrichment of plasma 
protease C1 inhibitor in NGs with BIS. For a detailed listing of the components of all protein 
coronae, please refer to the supporting information (Fig. S1 & S2 and Tables S4 & S5). 
Overall, we observe distinct tendencies for the association of the main components ApoB and 
HSA, depending on the starting materials used for the synthesis of NGs. An increase in 
hydrophilicity of NGs, whether by decreasing the temperature in pNIPAM, or the use of 
pNIPMAM, led to a decrease in ApoB and increase in dysopsonin content. The composition of 






The use of antifouling dPG proved to be essential for the inhibition of the protein absorption by 
NGs. Low protein amounts were found in all cases, however the presence of dPG allowed 
further decrease in a range of 10- to 13-fold. In order to isolate the elusive protein coronae 
around thermoresponsive NGs, we employed ultrafiltration that proved to be more efficient 
than the conventional centrifugation or size exclusion chromatography techniques. 
An ApoB-rich corona found around all NGs, except dPG-pNIPMAM, may enhance the targeting 
of liver LDL receptors, for the treatment of hyperlipidemia or other cholesterol-related diseases. 
[26] 
When used as nanogel components, pNIPMAM showed overall lower protein absorption than 
pNIPAM, especially when the latter was incubated in serum in its hydrophobic state, at 37 °C. 
dPG-pNIPAM NGs exhibited temperature-dependent protein coronae, with specific enrichment 
of Ig light chain above the pNIPAM LCST at 37 °C, together with interparticle aggregation in 
human serum as seen by DLS. This behavior reproduces what was observed by Koshkina et 
al. for poly(2-isopropyl-2-oxazoline) NPs showing pronounced aggregation in serum only 
above their LCST, [21] as well as resembling the IgG - driven bridging of polystyrene NPs, 
reported by Cukalevski et al. [28] An immunogenic response may originate from these features 
in the corona of dPG-pNIPAM NGs, such as triggering cytokine release from macrophages 
similar to what  Obst et al. observed in a previous report regarding the same NGs. [12]  
By designing thermoresponsive NGs, their recurring aggregation behavior in serum above their 
LCST [21] may be detrimental for their circulation in blood, and overall may increase the risk 
of thrombosis. However, smart thermoresponsive NGs that are able to switch to a hydrophobic 
conformation only upon external temperature regulation or an intrinsic temperature gradient, 
may increase their toxicity in situ, due to corona-dependent aggregation. In this way, one could 
boost the therapy efficacy. Analogously, the release of the protein corona upon sample cooling 
could be another strategy to deliver specific proteins, by applying external heating / cooling 
cycles. 
By changing the nature of the thermoresponsive polymer to pNIPMAM, a safer profile in serum 
was observed for all samples, together with a more hydrophilic protein corona, with a depletion 
of ApoB and α-2-macroglobulin, and a specific enrichment of serum albumin, transferrin and 
α-2-HS-glycoprotein. The same samples showed overall diminished protein absorption 
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Monomer used dPG content (w/w%)a Size @ 25 °C, d.nm (PDI)b Size @ 37 °C, d.nm (PDI)b
NIPAM 0* 250 (0.048) > 1000 (0.302)
NIPAM 5 184 (0.223) > 1000 (0.475)
NIPAM 15 190 (0.190) 170 (0.143)
NIPAM 33 276 (0.180) 220 (0.165)
NIPMAM 0* 171 (0.051) 190 (0.042)
NIPMAM 17 136 (0.226) 138 (0.206)
NIPMAM 33 140 (0.176) 144 (0.180)
NIPMAM 38 79 (0.186) 77 (0.190)
Table S1. Summarized data for the characterization of thermoresponsive pNIPAM and pNIPMAM nanogels according to nuclear magnetic 
resonance spectroscopy (a) and dynamic light scattering (b). 
*Samples having 0 dPG feed ratio were crosslinked with 4 mol% N,N’-methylenebisacrylamide. d.nm = hydrodynamic diameter, nm; PDI = 
polydispersity index.
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Temperature dependency of elusive protein corona around thermoresponsive nanogels: key interactions above the lower critical 
solution temperature 
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LOG2 Ratio H/L 




LOG2 Ratio H/L 
normalized B Mascot Score B # B (Count)
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 APOB_HUMAN 516651 0.29 -1.8 4225 50 0.24 -2.0 3444 50
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 71317 1.45 0.5 2935 48 1.61 0.7 3026 61
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 164613 0.60 -0.7 2006 46 0.59 -0.8 2291 41
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN 188569 1.13 0.2 2274 42 1.02 0.0 2213 40
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 79294 1.47 0.6 1394 30 1.38 0.5 1603 31
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 46878 1.19 0.3 532 15 1.09 0.1 734 17
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 HPT_HUMAN 45861 0.49 -1.0 574 15 0.83 -0.3 626 13
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 APOA1_HUMAN 30759 0.93 -0.1 508 13 1.08 0.1 399 9
Immunoglobulin heavy constant mu OS=Homo sapiens GN=IGHM PE=1 SV=4 IGHM_HUMAN 50093 0.68 -0.6 496 13 0.46 -1.1 448 12
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 CO4A_HUMAN 194261 0.86 -0.2 762 12 1.04 0.1 713 18
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 194170 0.91 -0.1 749 11 1.03 0.0 726 16
Immunoglobulin heavy constant alpha 1 OS=Homo sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 38486 1.13 0.2 221 8 0.88 -0.2 318 8
C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 69042 0.83 -0.3 471 7 0.69 -0.5 528 8
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 CERU_HUMAN 122983 0.93 -0.1 360 6 1.11 0.1 461 14
Immunoglobulin gamma-1 heavy chain OS=Homo sapiens PE=1 SV=1 IGG1_HUMAN 49926 1.12 0.2 331 6 0.94 -0.1 439 9
Immunoglobulin heavy constant gamma 3 OS=Homo sapiens GN=IGHG3 PE=1 SV=2 IGHG3_HUMAN 42287 1.27 0.3 268 6 0.86 -0.2 310 10
Immunoglobulin heavy constant gamma 2 OS=Homo sapiens GN=IGHG2 PE=1 SV=2 IGHG2_HUMAN 36505 0.89 -0.2 161 5 0.89 -0.2 286 8
Immunoglobulin heavy constant gamma 4 OS=Homo sapiens GN=IGHG4 PE=1 SV=1 IGHG4_HUMAN 36431 0.75 -0.4 170 5 0.83 -0.3 215 4
Immunoglobulin kappa light chain OS=Homo sapiens PE=1 SV=1 IGK_HUMAN 23650 1.15 0.2 337 5 1.24 0.3 440 5
Immunoglobulin kappa constant OS=Homo sapiens GN=IGKC PE=1 SV=2 IGKC_HUMAN 11929 1.08 0.1 261 5 1.24 0.3 295 5
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN 54790 1.30 0.4 233 4 0.99 0.0 220 4
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 AACT_HUMAN 47792 1.40 0.5 287 4 1.20 0.3 411 6
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 143680 1.04 0.1 526 4 0.76 -0.4 412 8
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 52385 1.05 0.1 235 4 1.05 0.1 302 10
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN 53025 0.96 -0.1 242 3 1.06 0.1 263 2
Immunoglobulin alpha-2 heavy chain OS=Homo sapiens PE=1 SV=1 IGA2_HUMAN 49817 1.32 0.4 138 3 0.90 -0.1 236 5
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 101782 0.65 -0.6 334 3 0.95 -0.1 354 3
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 ITIH2_HUMAN 106853 0.71 -0.5 216 3 0.63 -0.7 229 5
Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 ITIH4_HUMAN 103521 1.54 0.6 346 3 1.06 0.1 411 2
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 54526 2.07 1.0 206 3 1.34 0.4 102 2
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 A1AG1_HUMAN 23725 0.70 -0.5 70 2 0.99 0.0 250 3
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 FETUA_HUMAN 40098 1.80 0.9 43 2 1.60 0.7 91 2
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 KNG1_HUMAN 72996 0.89 -0.2 188 2 1.01 0.0 93 2
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 TTHY_HUMAN 15991 0.30 -1.7 71 2 0.74 -0.4 94 4







LOG2 Ratio H/L 
normalized C Mascot score C # C (Count) Mean H/L ratiop-value -LOG(P-value)
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 APOB_HUMAN 0.24 -2.1 3913 47 0.26 0.002 2.796
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 1.80 0.9 4284 59 1.61 0.017 1.759
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 0.69 -0.5 2182 39 0.62 0.010 2.010
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN 1.06 0.1 2480 55 1.07 0.155 0.809
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 1.62 0.7 1575 31 1.48 0.014 1.860
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 1.00 0.0 739 16 1.09 0.214 0.669
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 HPT_HUMAN 0.96 -0.1 661 14 0.73 0.264 0.579
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 APOA1_HUMAN 0.72 -0.5 396 5 0.90 0.456 0.342
Immunoglobulin heavy constant mu OS=Homo sapiens GN=IGHM PE=1 SV=4 IGHM_HUMAN 0.60 -0.7 512 10 0.57 0.041 1.391
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 CO4A_HUMAN 1.04 0.1 1012 21 0.97 0.707 0.151
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 1.03 0.0 1101 20 0.99 0.816 0.089
Immunoglobulin heavy constant alpha 1 OS=Homo sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 1.00 0.0 251 6 1.00 0.958 0.019
C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 1.08 0.1 434 8 0.85 0.339 0.470
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 CERU_HUMAN 1.30 0.4 602 11 1.10 0.434 0.363
Immunoglobulin gamma-1 heavy chain OS=Homo sapiens PE=1 SV=1 IGG1_HUMAN 0.89 -0.2 425 9 0.98 0.787 0.104
Immunoglobulin heavy constant gamma 3 OS=Homo sapiens GN=IGHG3 PE=1 SV=2 IGHG3_HUMAN 0.81 -0.3 296 8 0.96 0.801 0.096
Immunoglobulin heavy constant gamma 2 OS=Homo sapiens GN=IGHG2 PE=1 SV=2 IGHG2_HUMAN 0.96 -0.1 276 7 0.91 0.073 1.135
Immunoglobulin heavy constant gamma 4 OS=Homo sapiens GN=IGHG4 PE=1 SV=1 IGHG4_HUMAN 0.83 -0.3 199 4 0.80 0.019 1.717
Immunoglobulin kappa light chain OS=Homo sapiens PE=1 SV=1 IGK_HUMAN 1.02 0.0 529 6 1.13 0.150 0.823
Immunoglobulin kappa constant OS=Homo sapiens GN=IGKC PE=1 SV=2 IGKC_HUMAN 0.96 -0.1 477 6 1.09 0.361 0.443
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN 1.22 0.3 155 4 1.16 0.204 0.691
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 AACT_HUMAN 1.42 0.5 427 4 1.34 0.032 1.501
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 1.40 0.5 637 10 1.03 0.880 0.056
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 1.26 0.3 278 9 1.12 0.210 0.677
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN 0.79 -0.3 356 4 0.93 0.487 0.313
Immunoglobulin alpha-2 heavy chain OS=Homo sapiens PE=1 SV=1 IGA2_HUMAN 0.97 0.0 216 5 1.05 0.716 0.145
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 0.56 -0.8 435 5 0.70 0.150 0.825
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 ITIH2_HUMAN 0.73 -0.4 217 7 0.69 0.016 1.800
Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 ITIH4_HUMAN 1.00 0.0 484 4 1.18 0.351 0.455
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 1.62 0.7 231 8 1.65 0.058 1.239
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 A1AG1_HUMAN 1.43 0.5 81 2 1.00 0.989 0.005
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 FETUA_HUMAN 2.00 1.0 70 3 1.80 0.012 1.931
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 KNG1_HUMAN 1.29 0.4 203 5 1.05 0.702 0.153
Transthyretin OS=Homo sapiens GN=TTR PE=1 SV=1 TTHY_HUMAN 0.42 -1.3 107 3 0.46 0.095 1.022
Table S2 (follows). List of quantified proteins for Experiment 1 (Light = 33% dPG-PNIPAM (37°C), Heavy = 33% dPG-PNIPMAM (37 °C) , 18O-ratios according to the Mascot 









LOG2 Ratio H/L 
normalized A Mascot score A # A (Count)
Ratio H/L 
normalized B
LOG2 Ratio H/L 
normalized B Mascot score B # B (Count)
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 APOB_HUMAN 516651 1.92 0.9 3113 74 1.12 0.2 2664 49
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 71317 0.84 -0.3 3794 64 0.95 -0.1 2961 56
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN 188569 1.05 0.1 2307 43 1.02 0.0 2014 49
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 164613 1.28 0.4 2077 41 0.96 -0.1 1928 39
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 79294 0.90 -0.2 1162 28 0.99 0.0 1286 29
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 CO4A_HUMAN 194261 0.73 -0.4 839 26 0.79 -0.3 607 21
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 194170 0.78 -0.4 900 26 0.78 -0.4 658 20
Immunoglobulin heavy constant mu OS=Homo sapiens GN=IGHM PE=1 SV=4 IGHM_HUMAN 50093 1.56 0.6 707 17 1.08 0.1 332 12
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 46878 1.14 0.2 679 13 0.91 -0.1 764 18
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 HPT_HUMAN 45861 0.96 -0.1 552 13 0.87 -0.2 512 13
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 APOA1_HUMAN 30759 1.41 0.5 442 9 1.19 0.3 371 8
C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 69042 1.41 0.5 554 9 1.01 0.0 445 9
Immunoglobulin gamma-1 heavy chain OS=Homo sapiens PE=1 SV=1 IGG1_HUMAN 49926 1.68 0.7 306 9 1.22 0.3 344 8
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 52385 0.76 -0.4 285 8 0.97 0.0 196 7
Immunoglobulin heavy constant gamma 3 OS=Homo sapiens GN=IGHG3 PE=1 SV=2 IGHG3_HUMAN 42287 1.29 0.4 239 8 1.12 0.2 319 9
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 143680 0.64 -0.6 471 7 0.79 -0.3 272 5
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 101782 0.94 -0.1 524 7 1.03 0.0 488 6
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 ITIH2_HUMAN 106853 0.93 -0.1 313 7 0.80 -0.3 357 5
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 AACT_HUMAN 47792 0.98 0.0 317 6 0.98 0.0 307 6
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN 53025 0.92 -0.1 197 6 1.27 0.3 266 7
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 CERU_HUMAN 122983 0.81 -0.3 415 6 1.02 0.0 516 10
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 IC1_HUMAN 55347 0.66 -0.6 432 6 0.75 -0.4 242 3
Immunoglobulin heavy constant alpha 1 OS=Homo sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 38486 1.02 0.0 311 6 1.09 0.1 219 7
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN 54790 0.69 -0.5 227 5 0.95 -0.1 117 4
Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 HPTR_HUMAN 39518 1.07 0.1 246 5 0.90 -0.2 150 4
Immunoglobulin heavy constant gamma 2 OS=Homo sapiens GN=IGHG2 PE=1 SV=2 IGHG2_HUMAN 36505 1.16 0.2 203 5 1.15 0.2 238 6
Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 APOE_HUMAN 36246 1.63 0.7 269 4 0.95 -0.1 150 2
Immunoglobulin alpha-2 heavy chain OS=Homo sapiens PE=1 SV=1 IGA2_HUMAN 49817 1.19 0.2 164 4 1.03 0.0 216 6
Immunoglobulin kappa light chain OS=Homo sapiens PE=1 SV=1 IGK_HUMAN 23650 1.14 0.2 252 4 1.22 0.3 198 3
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 KNG1_HUMAN 72996 0.59 -0.8 117 3 1.14 0.2 85 4
Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 AMBP_HUMAN 39886 0.54 -0.9 167 2 0.73 -0.5 104 2
Immunoglobulin lambda-1 light chain OS=Homo sapiens PE=1 SV=1 IGL1_HUMAN 23101 1.92 0.9 112 2 1.48 0.6 58 2
Immunoglobulin kappa variable 3-20 OS=Homo sapiens GN=IGKV3-20 PE=1 SV=2 KV320_HUMAN 12663 1.22 0.3 107 2 1.44 0.5 123 2
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 54526 0.83 -0.3 123 2 0.82 -0.3 168 3
Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 VTNC_HUMAN 55069 0.66 -0.6 186 2 0.87 -0.2 200 2









normalized C Mascot score C # C (Count) Mean H/L ratio p-value -LOG(P-value)
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 APOB_HUMAN 1.35 0.4 2333 65 1.44 0.157 0.805
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 1.01 0.0 3574 65 0.94 0.282 0.550
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN 1.02 0.0 2898 60 1.04 0.180 0.744
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 1.08 0.1 1837 48 1.11 0.371 0.430
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 1.01 0.0 1372 24 0.97 0.423 0.374
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 CO4A_HUMAN 0.92 -0.1 693 21 0.81 0.068 1.165
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 0.92 -0.1 748 23 0.83 0.061 1.215
Immunoglobulin heavy constant mu OS=Homo sapiens GN=IGHM PE=1 SV=4 IGHM_HUMAN 1.13 0.2 433 12 1.25 0.209 0.680
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 0.87 -0.2 667 17 0.97 0.797 0.099
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 HPT_HUMAN 0.98 0.0 664 14 0.94 0.224 0.650
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 APOA1_HUMAN 1.23 0.3 286 7 1.28 0.052 1.281
C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 1.16 0.2 327 5 1.19 0.230 0.637
Immunoglobulin gamma-1 heavy chain OS=Homo sapiens PE=1 SV=1 IGG1_HUMAN 1.30 0.4 374 12 1.40 0.084 1.078
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 1.04 0.1 421 10 0.92 0.442 0.355
Immunoglobulin heavy constant gamma 3 OS=Homo sapiens GN=IGHG3 PE=1 SV=2 IGHG3_HUMAN 1.25 0.3 349 10 1.23 0.048 1.317
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 0.99 0.0 449 8 0.80 0.202 0.694
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 0.97 0.0 416 7 0.99 0.677 0.170
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 ITIH2_HUMAN 0.99 0.0 317 8 0.91 0.240 0.620
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 AACT_HUMAN 0.93 -0.1 404 7 0.97 0.329 0.483
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN 0.88 -0.2 209 7 1.02 0.897 0.047
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 CERU_HUMAN 0.97 0.0 547 9 0.94 0.405 0.393
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 IC1_HUMAN 0.87 -0.2 264 5 0.76 0.061 1.216
Immunoglobulin heavy constant alpha 1 OS=Homo sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 1.04 0.1 248 8 1.06 0.097 1.013
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN 0.93 -0.1 190 4 0.85 0.245 0.612
Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 HPTR_HUMAN 0.92 -0.1 306 6 0.97 0.660 0.180
Immunoglobulin heavy constant gamma 2 OS=Homo sapiens GN=IGHG2 PE=1 SV=2 IGHG2_HUMAN 1.29 0.4 244 6 1.21 0.024 1.617
Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 APOE_HUMAN 1.06 0.1 247 2 1.19 0.420 0.377
Immunoglobulin alpha-2 heavy chain OS=Homo sapiens PE=1 SV=1 IGA2_HUMAN 1.10 0.1 203 5 1.11 0.158 0.802
Immunoglobulin kappa light chain OS=Homo sapiens PE=1 SV=1 IGK_HUMAN 1.78 0.8 319 4 1.36 0.139 0.856
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 KNG1_HUMAN 0.77 -0.4 111 4 0.81 0.382 0.417
Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 AMBP_HUMAN 0.82 -0.3 40 2 0.69 0.083 1.080
Immunoglobulin lambda-1 light chain OS=Homo sapiens PE=1 SV=1 IGL1_HUMAN 1.54 0.6 190 4 1.65 0.030 1.523
Immunoglobulin kappa variable 3-20 OS=Homo sapiens GN=IGKV3-20 PE=1 SV=2 KV320_HUMAN 1.90 0.9 196 2 1.50 0.077 1.111
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 0.77 -0.4 210 3 0.81 0.021 1.675
Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 VTNC_HUMAN 0.87 -0.2 219 2 0.80 0.123 0.911
Table S3 (follows). List of quantified proteins for Experiment 2 (Light = 33% dPG-PNIPAM (25°C), Heavy = 33% dPG-PNIPAM (37°C), 18O-ratios according to the Mascot 








LOG2 Ratio H/L 
normalized A Mascot score A # A (Count)
Ratio H/L 
normalized B
LOG2 Ratio H/L 
normalized B Mascot score B # B (Count)
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 71317 1.67 0.7 5636 82 1.31 0.4 3983 57
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 APOB_HUMAN 516651 0.32 -1.7 3697 64 0.45 -1.2 2188 56
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN 188569 0.68 -0.6 2356 53 1.03 0.0 1728 48
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 79294 2.12 1.1 1513 46 1.52 0.6 1436 40
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 164613 0.32 -1.7 2459 41 0.64 -0.6 2067 39
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 46878 1.11 0.1 883 21 0.83 -0.3 726 18
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 194170 0.82 -0.3 1148 21 1.00 0.0 803 18
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 CO4A_HUMAN 194261 0.76 -0.4 1071 20 0.99 0.0 775 16
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 CERU_HUMAN 122983 1.30 0.4 702 19 1.24 0.3 660 16
Immunoglobulin heavy constant mu OS=Homo sapiens GN=IGHM PE=1 SV=4 IGHM_HUMAN 50093 0.09 -3.4 867 17 0.59 -0.8 375 9
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 HPT_HUMAN 45861 0.68 -0.6 714 15 0.56 -0.8 417 8
Immunoglobulin gamma-1 heavy chain OS=Homo sapiens PE=1 SV=1 IGG1_HUMAN 49926 1.41 0.5 329 12 1.12 0.2 368 10
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 APOA1_HUMAN 30759 0.44 -1.2 471 11 0.39 -1.4 375 10
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 52385 1.72 0.8 324 11 1.37 0.5 244 8
Immunoglobulin heavy constant alpha 1 OS=Homo sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 38486 0.90 -0.2 373 10 1.25 0.3 196 7
Immunoglobulin heavy constant gamma 3 OS=Homo sapiens GN=IGHG3 PE=1 SV=2 IGHG3_HUMAN 42287 1.19 0.3 321 9 0.96 -0.1 296 8
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 ITIH2_HUMAN 106853 0.65 -0.6 372 9 0.78 -0.4 254 9
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 54526 2.87 1.5 352 9 1.41 0.5 314 8
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN 54790 0.91 -0.1 257 8 1.20 0.3 191 6
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 143680 0.86 -0.2 748 8 0.87 -0.2 562 12
Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 HPTR_HUMAN 39518 0.86 -0.2 210 8 0.60 -0.7 220 6
Immunoglobulin kappa constant OS=Homo sapiens GN=IGKC PE=1 SV=2 IGKC_HUMAN 11929 1.00 0.0 436 8 0.61 -0.7 212 3
C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 69042 0.32 -1.6 519 7 0.66 -0.6 433 9
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 IC1_HUMAN 55347 0.82 -0.3 353 7 0.75 -0.4 317 6
Immunoglobulin lambda-1 light chain OS=Homo sapiens PE=1 SV=1 IGL1_HUMAN 23101 1.36 0.4 259 7 0.83 -0.3 167 2
Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 ITIH4_HUMAN 103521 1.13 0.2 412 7 0.99 0.0 396 7
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 KNG1_HUMAN 72996 1.44 0.5 339 7 1.13 0.2 160 4
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 AACT_HUMAN 47792 1.27 0.3 285 6 1.05 0.1 234 8
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN 53025 1.20 0.3 429 6 1.03 0.0 292 8
Immunoglobulin heavy constant gamma 4 OS=Homo sapiens GN=IGHG4 PE=1 SV=1 IGHG4_HUMAN 36431 1.24 0.3 186 6 1.00 0.0 154 6
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 101782 0.39 -1.4 583 6 0.68 -0.6 506 9
Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 CFAB_HUMAN 86847 1.16 0.2 383 5 1.10 0.1 308 6
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 AFAM_HUMAN 70963 1.61 0.7 250 4 1.56 0.6 181 5
Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 PLMN_HUMAN 93247 1.81 0.9 249 4 1.78 0.8 186 4
Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 VTNC_HUMAN 55069 0.98 0.0 161 4 1.15 0.2 187 5
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 A1AG1_HUMAN 23725 1.35 0.4 148 3 0.96 -0.1 106 3
Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 GELS_HUMAN 86043 1.39 0.5 216 3 1.04 0.1 155 6
Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 A1AG2_HUMAN 23873 1.05 0.1 74 2 0.90 -0.2 69 3
Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 AMBP_HUMAN 39886 0.43 -1.2 199 2 0.85 -0.2 110 2
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 ANGT_HUMAN 53406 1.00 0.0 292 2 1.09 0.1 305 4
Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 APOE_HUMAN 36246 0.45 -1.2 152 2 0.52 -1.0 146 2
Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 APOH_HUMAN 39584 1.97 1.0 113 2 1.82 0.9 95 5
Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3 HEP2_HUMAN 57205 0.97 0.0 134 2 1.46 0.5 109 3
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 HRG_HUMAN 60510 0.90 -0.1 112 2 1.34 0.4 160 3
Immunoglobulin alpha-2 heavy chain OS=Homo sapiens PE=1 SV=1 IGA2_HUMAN 49817 0.98 0.0 183 2 1.31 0.4 86 5
Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 THRB_HUMAN 71475 1.08 0.1 116 2 0.89 -0.2 125 2









normalized C Mascot score C # C (Count) Mean H/L ratio p-value -LOG(P-value)
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 1.33 0.4 3775 58 1.43 0.045 1.343
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 APOB_HUMAN 0.41 -1.3 2493 53 0.39 0.012 1.926
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN 0.96 -0.1 2274 52 0.88 0.411 0.386
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 1.45 0.5 1549 30 1.67 0.050 1.304
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 0.67 -0.6 2269 40 0.51 0.114 0.945
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 1.20 0.3 859 18 1.04 0.780 0.108
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 0.93 -0.1 921 20 0.91 0.273 0.564
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 CO4A_HUMAN 0.88 -0.2 928 19 0.87 0.213 0.671
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 CERU_HUMAN 1.11 0.2 738 13 1.21 0.053 1.274
Immunoglobulin heavy constant mu OS=Homo sapiens GN=IGHM PE=1 SV=4 IGHM_HUMAN 0.56 -0.8 533 9 0.31 0.193 0.714
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 HPT_HUMAN 0.77 -0.4 477 11 0.66 0.046 1.341
Immunoglobulin gamma-1 heavy chain OS=Homo sapiens PE=1 SV=1 IGG1_HUMAN 0.90 -0.1 373 11 1.13 0.454 0.343
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 APOA1_HUMAN 0.86 -0.2 344 5 0.53 0.123 0.910
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 1.45 0.5 303 9 1.51 0.026 1.579
Immunoglobulin heavy constant alpha 1 OS=Homo sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 0.93 -0.1 192 8 1.01 0.901 0.045
Immunoglobulin heavy constant gamma 3 OS=Homo sapiens GN=IGHG3 PE=1 SV=2 IGHG3_HUMAN 0.78 -0.4 418 8 0.96 0.776 0.110
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 ITIH2_HUMAN 0.61 -0.7 320 5 0.67 0.033 1.487
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 1.57 0.7 213 6 1.86 0.107 0.971
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN 1.56 0.6 203 5 1.19 0.374 0.427
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 0.93 -0.1 645 13 0.89 0.035 1.456
Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 HPTR_HUMAN 0.72 -0.5 311 5 0.72 0.085 1.070
Immunoglobulin kappa constant OS=Homo sapiens GN=IGKC PE=1 SV=2 IGKC_HUMAN 0.72 -0.5 232 4 0.76 0.204 0.690
C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 0.77 -0.4 659 9 0.55 0.155 0.809
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 IC1_HUMAN 0.91 -0.1 332 8 0.82 0.070 1.158
Immunoglobulin lambda-1 light chain OS=Homo sapiens PE=1 SV=1 IGL1_HUMAN 0.97 0.0 135 3 1.03 0.849 0.071
Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 ITIH4_HUMAN 1.67 0.7 373 6 1.23 0.321 0.494
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 KNG1_HUMAN 1.11 0.1 165 4 1.22 0.142 0.848
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 AACT_HUMAN 1.03 0.0 295 6 1.11 0.264 0.578
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN 1.16 0.2 265 8 1.13 0.126 0.899
Immunoglobulin heavy constant gamma 4 OS=Homo sapiens GN=IGHG4 PE=1 SV=1 IGHG4_HUMAN 0.84 -0.3 196 6 1.01 0.921 0.036
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 0.59 -0.8 478 5 0.54 0.068 1.167
Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 CFAB_HUMAN 1.24 0.3 336 9 1.16 0.049 1.312
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 AFAM_HUMAN 1.51 0.6 163 4 1.56 0.002 2.758
Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 PLMN_HUMAN 1.42 0.5 255 4 1.66 0.022 1.651
Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 VTNC_HUMAN 1.22 0.3 110 4 1.11 0.256 0.592
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 A1AG1_HUMAN 1.69 0.8 166 4 1.30 0.256 0.592
Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 GELS_HUMAN 1.42 0.5 127 2 1.27 0.143 0.844
Alpha-1-acid glycoprotein 2 OS=Homo sapiens GN=ORM2 PE=1 SV=2 A1AG2_HUMAN 1.64 0.7 93 2 1.16 0.509 0.293
Protein AMBP OS=Homo sapiens GN=AMBP PE=1 SV=1 AMBP_HUMAN 1.37 0.5 171 3 0.79 0.562 0.250
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 ANGT_HUMAN 1.27 0.3 211 4 1.11 0.269 0.571
Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 APOE_HUMAN 0.86 -0.2 211 2 0.58 0.112 0.953
Beta-2-glycoprotein 1 OS=Homo sapiens GN=APOH PE=1 SV=3 APOH_HUMAN 2.00 1.0 103 4 1.93 0.002 2.672
Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3 HEP2_HUMAN 1.23 0.3 163 3 1.20 0.256 0.593
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 HRG_HUMAN 1.16 0.2 103 3 1.12 0.428 0.369
Immunoglobulin alpha-2 heavy chain OS=Homo sapiens PE=1 SV=1 IGA2_HUMAN 0.87 -0.2 149 5 1.03 0.807 0.093
Prothrombin OS=Homo sapiens GN=F2 PE=1 SV=2 THRB_HUMAN 0.93 -0.1 91 2 0.96 0.592 0.228
Table S4 (follows). List of quantified proteins for Experiment 3 (Light = 33% dPG-PNIPAM (25°C), Heavy = PNIPAM/BIS (25 °C), 18O-ratios according to the Mascot Distiller 
software (version 2.6.1.0 [Matrix Science Ltd, London, UK]).
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Fig. S1 Volcano plot for the enriched proteins found in the protein coronae around 33 w/w% 
dPG – pNIPAM and pNIPAM/BIS nanogels incubated in human serum for 1 h at 25 °C. Proteins 
were highlighted (red labels) if their mean H/L ratio (n=3) indicated more than 1.5-fold 
enrichment (mean H/L < 0.66 or mean H/L > 1.5). Mean H/L ratios with p-values ≤ 0.05 (-log(p) 










LOG2 Ratio H/L 
normalized A Mascot score A # A (Count)
Ratio H/L 
normalized B
LOG2 Ratio H/L 
normalized B
Mascot score 
B # B (Count)
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN 188569 1.10 0.1 3159 67 1.05 0.1 2969 63
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 71317 1.22 0.3 4737 60 1.21 0.3 4189 52
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 APOB_HUMAN 516651 0.73 -0.4 3210 46 0.48 -1.0 3272 38
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 79294 1.14 0.2 2323 42 1.01 0.0 1592 36
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 164613 0.80 -0.3 2273 40 0.79 -0.3 2359 40
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 CO4A_HUMAN 194261 1.00 0.0 1115 24 0.94 -0.1 893 21
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 194170 1.02 0.0 1090 24 0.94 -0.1 933 21
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 46878 1.10 0.1 769 22 1.04 0.1 608 22
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 CERU_HUMAN 122983 0.96 -0.1 682 21 1.05 0.1 580 17
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 HPT_HUMAN 45861 0.61 -0.7 674 14 0.77 -0.4 632 15
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 143680 0.77 -0.4 709 12 0.61 -0.7 659 9
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 APOA1_HUMAN 30759 1.32 0.4 501 11 1.30 0.4 432 11
Immunoglobulin heavy constant mu OS=Homo sapiens GN=IGHM PE=1 SV=4 IGHM_HUMAN 50093 0.80 -0.3 442 11 1.02 0.0 341 12
Immunoglobulin heavy constant gamma 3 OS=Homo sapiens GN=IGHG3 PE=1 SV=2 IGHG3_HUMAN 42287 1.30 0.4 288 10 0.92 -0.1 232 9
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 ITIH2_HUMAN 106853 0.69 -0.5 482 10 0.63 -0.7 488 8
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 52385 0.99 0.0 430 9 0.85 -0.2 355 9
Immunoglobulin heavy constant alpha 1 OS=Homo sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 38486 1.00 0.0 416 9 0.99 0.0 279 8
Immunoglobulin gamma-1 heavy chain OS=Homo sapiens PE=1 SV=1 IGG1_HUMAN 49926 1.26 0.3 320 8 1.06 0.1 260 10
Immunoglobulin mu heavy chain OS=Homo sapiens PE=1 SV=1 IGM_HUMAN 64244 0.82 -0.3 404 8 0.93 -0.1 280 9
Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 ITIH4_HUMAN 103521 0.98 0.0 614 8 1.02 0.0 437 2
Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 HPTR_HUMAN 39518 0.80 -0.3 350 7 0.54 -0.9 441 7
Immunoglobulin alpha-2 heavy chain OS=Homo sapiens PE=1 SV=1 IGA2_HUMAN 49817 1.29 0.4 197 7 1.31 0.4 164 4
Immunoglobulin kappa constant OS=Homo sapiens GN=IGKC PE=1 SV=2 IGKC_HUMAN 11929 0.93 -0.1 321 7 1.07 0.1 272 5
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN 54790 0.84 -0.2 233 6 0.98 0.0 118 3
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 AACT_HUMAN 47792 1.28 0.4 341 6 1.18 0.2 492 8
C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 69042 1.08 0.1 461 6 1.03 0.0 359 5
Immunoglobulin kappa light chain OS=Homo sapiens PE=1 SV=1 IGK_HUMAN 23650 0.90 -0.1 294 6 0.91 -0.1 310 4
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 101782 0.82 -0.3 577 6 0.68 -0.6 592 10
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 54526 0.89 -0.2 209 6 1.06 0.1 485 7
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN 53025 0.91 -0.1 313 5 1.28 0.4 560 7
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 FETUA_HUMAN 40098 1.31 0.4 133 5 0.83 -0.3 225 5
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 IC1_HUMAN 55347 0.62 -0.7 365 5 0.57 -0.8 426 6
Immunoglobulin lambda-1 light chain OS=Homo sapiens PE=1 SV=1 IGL1_HUMAN 23101 1.10 0.1 215 5 1.18 0.2 116 3
Immunoglobulin heavy constant gamma 2 OS=Homo sapiens GN=IGHG2 PE=1 SV=2 IGHG2_HUMAN 36505 1.19 0.3 268 4 0.99 0.0 265 8
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 AFAM_HUMAN 70963 0.35 -1.5 142 3 1.31 0.4 87 2
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 ANGT_HUMAN 53406 0.97 -0.1 372 3 0.89 -0.2 338 3
Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 CFAB_HUMAN 86847 0.67 -0.6 310 3 0.98 0.0 339 6
Immunoglobulin heavy constant gamma 4 OS=Homo sapiens GN=IGHG4 PE=1 SV=1 IGHG4_HUMAN 36431 1.19 0.3 236 3 1.05 0.1 221 6
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 KNG1_HUMAN 72996 1.23 0.3 253 3 0.55 -0.9 207 3
Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 VTNC_HUMAN 55069 1.21 0.3 135 3 0.95 -0.1 234 2
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 A1AG1_HUMAN 23725 1.88 0.9 181 2 1.28 0.4 149 2
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 APOA4_HUMAN 45371 1.26 0.3 232 2 1.61 0.7 192 2
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 HRG_HUMAN 60510 1.30 0.4 188 2 1.03 0.0 161 2
Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 PLMN_HUMAN 93247 1.44 0.5 320 2 1.09 0.1 263 2









LOG2 Ratio H/L 
normalized C Mascot score C # C (Count) Mean H/L ratio p-value -LOG(P-value)
Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN 1.13 0.2 3096 62 1.09 0.061 1.215
Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 1.34 0.4 5046 60 1.25 0.022 1.657
Apolipoprotein B-100 OS=Homo sapiens GN=APOB PE=1 SV=2 APOB_HUMAN 0.66 -0.6 3733 51 0.62 0.061 1.217
Serotransferrin OS=Homo sapiens GN=TF PE=1 SV=3 TRFE_HUMAN 1.08 0.1 2349 32 1.07 0.195 0.711
Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 1.10 0.1 1860 39 0.89 0.383 0.417
Complement C4-A OS=Homo sapiens GN=C4A PE=1 SV=2 CO4A_HUMAN 0.94 -0.1 1178 27 0.96 0.188 0.725
Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 0.95 -0.1 1181 27 0.97 0.329 0.483
Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN 1.04 0.1 1002 27 1.06 0.103 0.989
Ceruloplasmin OS=Homo sapiens GN=CP PE=1 SV=1 CERU_HUMAN 1.12 0.2 818 17 1.04 0.500 0.301
Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=1 HPT_HUMAN 0.80 -0.3 829 13 0.72 0.060 1.219
Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 0.94 -0.1 824 12 0.76 0.159 0.800
Apolipoprotein A-I OS=Homo sapiens GN=APOA1 PE=1 SV=1 APOA1_HUMAN 1.42 0.5 494 9 1.35 0.007 2.136
Immunoglobulin heavy constant mu OS=Homo sapiens GN=IGHM PE=1 SV=4 IGHM_HUMAN 0.86 -0.2 371 12 0.89 0.235 0.629
Immunoglobulin heavy constant gamma 3 OS=Homo sapiens GN=IGHG3 PE=1 SV=2 IGHG3_HUMAN 1.11 0.2 258 8 1.10 0.447 0.349
Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=2 ITIH2_HUMAN 0.68 -0.6 426 8 0.67 0.005 2.279
Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 0.96 -0.1 372 10 0.93 0.277 0.558
Immunoglobulin heavy constant alpha 1 OS=Homo sapiens GN=IGHA1 PE=1 SV=2 IGHA1_HUMAN 0.89 -0.2 390 7 0.96 0.394 0.405
Immunoglobulin gamma-1 heavy chain OS=Homo sapiens PE=1 SV=1 IGG1_HUMAN 1.15 0.2 302 10 1.15 0.098 1.008
Immunoglobulin mu heavy chain OS=Homo sapiens PE=1 SV=1 IGM_HUMAN 0.85 -0.2 320 10 0.86 0.055 1.262
Inter-alpha-trypsin inhibitor heavy chain H4 OS=Homo sapiens GN=ITIH4 PE=1 SV=4 ITIH4_HUMAN 1.01 0.0 432 6 1.00 0.959 0.018
Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=2 SV=2 HPTR_HUMAN 1.36 0.4 425 10 0.84 0.575 0.241
Immunoglobulin alpha-2 heavy chain OS=Homo sapiens PE=1 SV=1 IGA2_HUMAN 0.98 0.0 149 5 1.18 0.209 0.680
Immunoglobulin kappa constant OS=Homo sapiens GN=IGKC PE=1 SV=2 IGKC_HUMAN 1.48 0.6 304 5 1.14 0.442 0.354
Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN 1.37 0.5 254 7 1.04 0.800 0.097
Alpha-1-antichymotrypsin OS=Homo sapiens GN=SERPINA3 PE=1 SV=2 AACT_HUMAN 0.99 0.0 532 9 1.14 0.212 0.675
C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 0.87 -0.2 625 9 0.99 0.896 0.048
Immunoglobulin kappa light chain OS=Homo sapiens PE=1 SV=1 IGK_HUMAN 1.28 0.4 305 4 1.02 0.904 0.044
Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 0.84 -0.3 766 13 0.77 0.059 1.232
Vitamin D-binding protein OS=Homo sapiens GN=GC PE=1 SV=1 VTDB_HUMAN 1.09 0.1 494 8 1.01 0.887 0.052
Antithrombin-III OS=Homo sapiens GN=SERPINC1 PE=1 SV=1 ANT3_HUMAN 0.98 0.0 505 6 1.04 0.734 0.135
Alpha-2-HS-glycoprotein OS=Homo sapiens GN=AHSG PE=1 SV=1 FETUA_HUMAN 1.11 0.2 175 5 1.07 0.678 0.169
Plasma protease C1 inhibitor OS=Homo sapiens GN=SERPING1 PE=1 SV=2 IC1_HUMAN 0.63 -0.7 423 8 0.61 0.004 2.396
Immunoglobulin lambda-1 light chain OS=Homo sapiens PE=1 SV=1 IGL1_HUMAN 1.32 0.4 163 3 1.20 0.077 1.114
Immunoglobulin heavy constant gamma 2 OS=Homo sapiens GN=IGHG2 PE=1 SV=2 IGHG2_HUMAN 1.08 0.1 156 6 1.08 0.279 0.555
Afamin OS=Homo sapiens GN=AFM PE=1 SV=1 AFAM_HUMAN 0.94 -0.1 133 2 0.76 0.550 0.260
Angiotensinogen OS=Homo sapiens GN=AGT PE=1 SV=1 ANGT_HUMAN 0.96 -0.1 367 5 0.94 0.134 0.873
Complement factor B OS=Homo sapiens GN=CFB PE=1 SV=2 CFAB_HUMAN 0.96 -0.1 347 11 0.86 0.341 0.468
Immunoglobulin heavy constant gamma 4 OS=Homo sapiens GN=IGHG4 PE=1 SV=1 IGHG4_HUMAN 0.95 -0.1 196 3 1.06 0.481 0.318
Kininogen-1 OS=Homo sapiens GN=KNG1 PE=1 SV=2 KNG1_HUMAN 0.56 -0.8 255 4 0.72 0.347 0.460
Vitronectin OS=Homo sapiens GN=VTN PE=1 SV=1 VTNC_HUMAN 1.10 0.1 229 4 1.08 0.387 0.412
Alpha-1-acid glycoprotein 1 OS=Homo sapiens GN=ORM1 PE=1 SV=1 A1AG1_HUMAN 1.22 0.3 207 3 1.43 0.122 0.913
Apolipoprotein A-IV OS=Homo sapiens GN=APOA4 PE=1 SV=3 APOA4_HUMAN 1.16 0.2 192 2 1.33 0.100 1.001
Histidine-rich glycoprotein OS=Homo sapiens GN=HRG PE=1 SV=1 HRG_HUMAN 0.82 -0.3 230 3 1.03 0.825 0.084
Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 PLMN_HUMAN 1.13 0.2 400 2 1.21 0.163 0.789
Table S5 (follows). List of quantified proteins for Experiment 4 (Light = PNIPMAM/BIS (37°C), Heavy = 33% dPG-PNIPMAM (37°C), 18O-ratios according to the Mascot Distiller 























Fig. S2. Volcano plot for the enriched proteins found in the protein coronae around 
pNIPMAM/BIS and 33 w/w% dPG – pNIPMAM nanogels incubated in human serum for 1 h at 
37 °C. Proteins were highlighted (red labels) if their mean H/L ratio (n=3) indicated more than 
1.5-fold enrichment (mean H/L < 0.66 or mean H/L > 1.5). Mean H/L ratios with p-values ≤ 
0.05 (-log(p) ≥ 1.3) were considered significant.  
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3.2 Protein Corona Formation on Colloidal Polymeric Nanoparticles and 
Polymeric Nanogels: Impact on Cellular Uptake, Toxicity, Immunogenicity, and 
Drug Release Properties 
K. Obst, G. Yealland, B. Balzus, E. Miceli, M. Dimde, C. Weise, M. Eravci, R. Bodmeier, R. 
Haag, M. Calderón, N. Charbaji, S. Hedtrich, Biomacromolecules 2017, 18, 1762. 
https://doi.org/10.1021/acs.biomac.7b00158 
Author contribution: In this work, the author carried out the synthesis and characterization of 
thermoresponsive dPG-pNIPAM nanogels, as well as contributing to the data analysis, 
scientific discussion and the writing of a section of the manuscript. 
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3.3  Semi-interpenetrated, dendritic, dual-responsive nanogels with 
cytochrome c corona induce controlled apoptosis in HeLa cells 
E. Miceli, S. Wedepohl, E. R. Osorio Blanco, G. N. Rimondino, M. Martinelli, M. Strumia, M. 
Molina, M. Kar, M. Calderón, manuscript submitted. 
Fig. 3.3 A preassembled cytochrome c corona may be released upon nanogel swelling at 30 
°C, inducing apoptosis in HeLa cells under controlled conditions. 
Author contribution: The author was responsible for the overall concept, for the syntheses, 
characterizations, protein corona formation, in vitro release studies of cytochrome c, and 
sample preparation for apoptosis study on HeLa cells. 
Abstract: Poly(N-isopropylacrylamide) (pNIPAM)-based NGs were involved in the release of 
a therapeutic protein corona by temperature decrease. NGs based on dendritic polyglycerol 
(dPG) and thermoresponsive pNIPAM were semi-interpenetrated with poly(4-acryloylamine-4-
(carboxyethyl)heptanodioic acid) (pABC). The resulting semi-interpenetrated NGs retain the 
thermoresponsive properties of pNIPAM, together with pH-responsive, dendritic pABC as a 
secondary network, in one single nanoparticle. A cytochrome c (cyt c) corona was formed on 
SIPN NGs in their collapsed state (37 °C). Upon cooling of the samples to room temperature, 
the swelling of the NG effectively boosted the release of cyt c, as compared with the same kept 
at constant 37 °C. These responsive SIPN NGs were able to deliver cyt c to cancer cells and 
specifically induce apoptosis at 30 °C, while the cells remained largely unaffected at 37 °C. 
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Abstract Poly(N-isopropylacrylamide) (pNIPAM)-based NGs were involved in the release 
of a therapeutic protein corona by temperature decrease. NGs based on dendritic polyglycerol 
(dPG) and thermoresponsive pNIPAM were semi-interpenetrated with poly(4-acryloylamine-4-
(carboxyethyl)heptanodioic acid) (pABC). The resulting semi-interpenetrated NGs retain the 
thermoresponsive properties of pNIPAM, together with pH-responsive, dendritic pABC as a 
secondary network, in one single nanoparticle. A cytochrome c (cyt c) corona was formed on 
SIPN NGs in their collapsed state (37 °C). Upon cooling of the samples to room temperature, 
the swelling of the NG effectively boosted the release of cyt c, as compared with the same kept 
at constant 37 °C. These responsive SIPN NGs were able to deliver cyt c to cancer cells and 
specifically induce apoptosis at 30 °C, while the cells remained largely unaffected at 37 °C. In 
this way, we show therapeutic efficacy of thermoresponsive NGs as protein carriers and their 
efficacy triggered by temperature decrease. We envision the use of such thermal trigger as 
relevant for the treatment of superficial tumors, in which induction of apoptosis can be 
controlled by the application of local cooling agents. 
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Introduction 
Nanogels (NGs) are three-dimensional crosslinked nanoparticles that are able to absorb a 
large amount of water. They constitute a powerful class of new nanocarriers for the loading 
and improved release in situ of hydrophilic cargoes (both small molecules or macromolecules) 
in controlled conditions. Their ease of functionalization with dyes or inorganic imaging agents 
allows them to be used as powerful diagnostic agents, in an effort to combine therapeutic 
efficacy and diagnostics in one single theranostic macromolecule. [1] Their nanosized 
dimensions allow for an increased residence time in the bloodstream by avoiding excretion 
from the kidneys, [2] as well as for enhanced skin [3] and follicular penetration [4] or improved 
mucosal adhesion. [5] Stimuli-responsive NGs are capable of changing their physicochemical 
properties upon exposure to external conditions such as temperature, pH, reducing conditions, 
light, and magnetic field, among others. These „smart“ materials offer new promising 
perspectives for the development of next generation agents for the controlled delivery of drugs. 
[6] Thermoresponsive polymers exhibit a reversible phase transition, caused by the 
hydrophobic aggregation upon heating of their aqueous solutions to temperatures above their 
lower critical solution temperature (LCST). Poly(N-isopropylacrylamide) (pNIPAM) undergoes 
this phase transition at around 33 °C. [7] Thermoresponsive NGs based on N-
isopropylacrylamide (NIPAM) are one of the main candidates for biomedical research due to 
their reversible phase transition at a temperature of 33 °C, close to the body temperature. [8] 
pNIPAM NGs crosslinked with dendritic polyglycerol (dPG), [9] were published by our group, 
showing a versatility for their use in biomedical applications. The copolymerization of pNIPAM 
with poly(N-isopropylmethacrylamide) (pNIPMAM) or hydrophilic comonomers, such as 
acrylamide or acrylic acid, helps tuning the LCST values to a more desired transition 
temperature, closer to 37 °C. [10] The use of dPG as a macromolecular crosslinker helps 
improving the biocompatibility of pNIPAM, as well as avoiding the pNIPAM-driven NG 
aggregation above the LCST, thus ensuring the colloidal stability of dPG-pNIPAM NGs under 
physiological conditions. [9] The high swelling abilities of NGs can be exploited to achieve high 
loadings of bioactives. [11] This property, combined with the abrupt shrinkage of the 
thermoresponsive network upon temperature change, gives NGs unique properties for the 
controlled release of small drugs, as well as biomacromolecules, in a controlled fashion. 
Dendrons are molecules with regular branching points and symmetrical tree-like structures. At 
their extremity, the repeated end groups may induce multivalency, leading to an exponential 
increase in binding affinities. [12] In some cases though, multivalency is counteracted by steric 
crowding which may hinder the multivalent effects, leading to a binding saturation point, in an 
anti-cooperative fashion. [13] The tuning of the generation (number of repeated branchings) 
allows the regulation of the hydrophilic/hydrophobic balance of the dendron. [14] In this way, 
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one can tune the binding affinity towards guest molecules, whether these are small molecules, 
proteins, dendrons, or polymers. [15] Newkome-type dendrons / dendrimers are a class of 
molecules that are biocompatible, non-toxic and are used to create polymers with 
multifunctional acidic units, useful for promoting host-guest interactions with therapeutic 
relevant moieties. [16] Among this class of dendrons, 4-acryloylamine-4-
(carboxyethyl)heptanodioic acid (ABC) and its copolymer NGs with pNIPAM have been 
developed by our group and have been proven to provide sustained release of cisplatin at 
lysosomal conditions. [17] Following a similar approach, we used ABC in this study to generate 
semi-interpenetrated NGs with dendritic multifunctional units that can be used as anchoring 
points for the binding of therapeutic proteins. Semi-interpenetrated polymer networks (SIPNs) 
are composed by more than one polymeric network that are physically entangled, although not 
covalently bound to each other. As a result, the different networks cannot be separated by 
simple mechanical stress, but rather only by chemical reactions. This approach is useful for 
the fabrication of polymer composites that retain the physicochemical properties of the 
individual networks. SIPN NGs can be synthesized by a two-step process, in which the 
secondary network is being polymerized inside the preformed NG. By controlling the synthetic 
parameters of the polymerization, the resulting SIPN concentrations can be optimized in order 
to get chain lengths that can be exposed to the NG surface ideally only upon shrinkage of the 
thermoresponsive NG scaffolds. Our group has developed dPG-pNIPAM SIPN NGs with 
polymerized 2- acrylamido- 2- methylpropane sulfonic acid (AMPS) or 
dimethylaminoethylmethacrylate (DMAEM) as vectors for the efficient delivery of doxorubicin 
to the resistant KB-V1 cell line. [18] Their incorporation into honeycomb films for controlled 
bovine serum albumin (BSA) delivery was also investigated and described by our group in a 
follow-up study. [19] Their copolymeric NG analogues were reported in another case study for 
the sustained delivery of doxorubicin and methotrexate. [20] In another report, we employed 
dPG-PNIPAM SIPN NGs with poly(aniline) as secondary network, a near infrared - active 
polymer to add photothermal reactivity to the NGs. [21] Several other examples of SIPN NGs 
can be found in literature, showing a broad range of applications for this synthetic approach, 
for the development of next generation nanoparticles for biomedical applications. [22]  
The use of protein drugs has advantages over conventional chemotherapy agents, due to their 
inherent lower toxicities combined with high specificities. The presence of a protein corona has 
a profound impact on the biological efficacy of nanoparticles, and by designing tailor-made 
protein corona one could boost the therapeutic efficacy of the nanoparticle, [23] in a synergistic 
effort to combine efficient nanosized vectors to therapeutic proteins. [24] Cytochrome c (cyt c) 
is a small, 12 kDa heme protein with an isoelectric point (pI) of 10 and is therefore positively 
charged at a physiological pH of 7.4. In cells, cyt c is loosely associated to the inner membrane 
of the mitochondria and is involved as an intermediate in the electron transport chain. If 
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released into the cytosol, cyt c triggers apoptosis by binding to apoptosis activating factor-1 
(Apaf-1). This in turn is responsible for the activation of caspase-9 to initiate the intrinsic 
apoptotic cascade. [25] While cyt c itself is membrane-impermeable, recent studies involved the 
use of nanoparticles (NPs) for sustained cytosolic release of cyt c. Different nanoparticle-based 
systems have been evaluated for the activation of apoptosis following cyt c release: 
mesoporous SiO2 NPs [26] or a combination of end-capped cyt c and encapsulated doxorubicin, 
[27] crosslinked cyt c – based NPs [28] or redox-sensitive hyaluronic acid NGs. [29] To our 
knowledge however, none of these studies investigate the temperature-dependent cyt c 
activation for controlled induction of apoptosis. 
In this work, we describe the synthesis of dendritic SIPN NGs, based on thermoresponsive 
dPG-pNIPAM NGs, with pABC as a SIPN (Fig. 1). This arrangement forms NGs which maintain 
the original thermoresponsiveness of pNIPAM, together with dPG to provide colloidal stability 
at a temperature higher than the pNIPAM LCST (33 °C), combined with pH-sensitive dendritic 
pABC or monofunctional control poly(acrylic acid) (pAA) as SIPN. We characterized the NGs 
via UV-VIS, nuclear magnetic resonance spectroscopy (NMR), and dynamic light scattering 
(DLS). These NGs were loaded with cyt c at 37 °C, to form a corona around the collapsed NG, 
by binding pABC or pAA on the NG surface. The subsequent swelling of the NGs at 25 °C was 
investigated in relation with its ability to disrupt the corona, thereby triggering the release of cyt 
c. The temperature-controlled delivery of cyt c was evaluated in vitro in HeLa cells, where the
ability of the cyt c-laden NGs to induce apoptosis by controlled intracellular delivery of cyt c 
was probed. In this way, we combined dendritic NG design with the use of a thermal trigger in 
order to achieve full control on the reactivity of a therapeutic protein. Thus, we introduce a 
model system for the development of NG-based therapeutics for the treatment of superficial 
tumors or skin diseases, where local cooling may be efficiently applied. 
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Fig. 1 (a) Schematic representation of the polymerization of 4-acryloylamine-4-
(carboxyethyl)heptanodioic acid inside the preformed dendritic polyglycerol - poly(N-
isopropylacrylamide) nanogels (b) Formation of cytochrome c corona.  
Materials and Methods 
All materials were purchased by Sigma, except 2,2-azobis(2-methyl-N-(2-hydroxyethyl)-
propionamide) (VA-086), which was purchased by Wako Ltd. 
The syntheses of dPG-PNIPAM NGs and ABC have been previously published.[9, 17] The 
synthesis of SIPN NGs proceeded as follows: 50 mg of lyophilized dPG-PNIPAM NG were 
soaked in a 5 mL solution of ABC or AA in a concentration range of 0.3-2.6 mg mL-1 at 0 °C 
for 16 h. The solution was then purified by ultrafiltration (molecular weight cut-off MWCO = 1 
MDa), then 2 mg VA-086 were added and the solution was purged for 30 min under Ar flow. 
The polymerization was then initiated by light irradiation for 1 min and kept running for 4 h in 
an ice bath. The solution was dialyzed (MWCO = 50 kDa) against water and ultimately freeze-
dried, to obtain NGs as a cotton-like powder. 
The cyt c corona formation was done by mixing 200 μL of a 20 mg mL-1 solution of SIPN NG 
and 200 μL of a 20 mg mL-1 cyt c solution both in phosphate buffered saline (PBS), for 4 h at 
37 °C. The solution was then purified by ultrafiltration (MWCO = 1 MDa), by short centrifugation 
cycles at 5000 x g of maximum 10 s, in order to not cool down the sample, to prevent NG 
swelling. Repeated centrifugation and warming cycles are needed in order to wash with 2 mL 
PBS volume through the cartridge. The cyt c amount was quantified by UV-VIS spectroscopy, 
by measuring absorbance at λ = 530 nm. 
Hydrodynamic diameters were measured by dynamic light scattering (DLS) in a Malvern 
Zetasizer instrument with a He–Ne laser (λ = 633 nm) and scattering angle of 173°. All the 
samples were prepared at 1 mg mL-1 in 10 mM PBS at pH 7.4 and a 150 mM ionic strength. 
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For ζ-potential measurements, the NGs’ electrophoretic mobility was analyzed following 
application of a 20 V cm-1 electric field and converted into the ζ-potential according to the 
Helmholtz-Smoluchowski equation. 
Nuclear magnetic resonance spectra (NMR) were recorded on a Bruker AVANCE III 700, 700 
MHz at 25 °C or 45 °C in deuterated water. Data were analyzed using the MestreNova software 
package. 
Transition temperatures were measured on a Cary 100 Bio UV-vis spectrophotometer 
equipped with a temperature-controlled, six-position sample holder. Buffer NG solutions (1 mg 
mL-1) were heated at 0.2 °C min-1 while monitoring both the transmittance at 500 nm (1 cm 
path length) and the solution temperature (from 15 to 65 °C), as determined by the internal 
temperature probe. The cloud point temperature (Tcp) of each NG was determined using the 
minimum of the first derivative of the graph % transmittance vs. temperature. 
Release studies were conducted inside an ultrafiltration cartridge (MWCO = 1 MDa). Fast 
repeated centrifugation cycles (10s at 5000 xg) were used in order to avoid sample cooling. 
The collection of the filtrate at different times and quantifiying cyt c by means of absorbance 
measurement at λ = 530 nm, led to the quantification of the released cyt c. Repeated 
experiments at 37 °C and 25 °C were performed by the identical procedure. 
For the apoptosis assay, 1x105 HeLa cells mL-1 were seeded into 96 well plates and incubated 
overnight. The next day, the supernatant was discarded and replaced by 100 µL/well fresh 
medium with dilutions of compounds. The cyt c concentration served as the basis for dilution 
calculations and equal volumes of the respective unloaded NGs were applied. Samples and 
cells were kept at temperatures above 37 °C using a heating block and a heating plate. 10-fold 
serial dilutions were prepared in a 96-well plate placed on the heat plate at 40 °C. Dilutions for 
duplicate wells were prepared independently. Two identical plates were prepared. Incubations 
were done in two regular cell culture incubators set to 37 °C or 30 °C and 5% CO2. One plate 
was incubated in at 37 °C for 2 h (presumed uptake phase), then at 30 °C over night (release 
phase), then 4 h @37 °C (apoptosis induction phase). The other identical plate was incubated 
in parallel but at 37 °C only. Induction of Caspase 3/7 activity was measured using the 
Caspase-Glo® 3/7 Assay System (Promega) according to the instructions of the manufacturer. 
91 
Results and discussion 
Synthesis and characterization of SIPN nanogels 
The dPG-pNIPAM NGs and ABC were synthesized according to procedures published 
previously by our group. [9, 17] To perform semi-interpenetration, the lyophilized NGs were 
soaked in a concentrated aqueous solution of ABC or acrylic acid (AA). ABC or AA were 
present in a concentration range of 0.3 - 2.6 mg mL-1 in the NGs solution (10 mg mL-1). After 
purification by ultracentrifugation, the SIPN formation occurred via radical polymerization of 
the acrylic monomer inside the NGs. The light activation of 0.3 mg mL-1 2,2'-azobis(2-methyl-
N-(2-hydroxyethyl)propionamide) (VA-086) was used to initiate the radical polymerization of 
the SIPN. After 4 h of polymerization, the conversion of pABC or pAA in the resulting SIPN 
NGs was found to be in the range of 12% - 26%, as determined by NMR. These low values 
may indicate a lack of affinity between ABC or AA and dPG-pNIPAM NG scaffolds to boost 
their encapsulation, combined with the porous conformation of the NGs. Table 1 shows the 
values obtained from characterization of a panel of SIPN NGs. Different ratios were screened 
to obtain SIPN with increasing concentrations inside the NGs. 
Table 1. Summary of the data for the characterization of the screened conditions for semi-














Temperature 25 °C 45 °C 
pABC 
0.2 137 (0.187) -1.3 104 (0.096) -3.1 
0.5 130 (0.200) +0.4 97 (0.076) -2.4 
0.9 128 (0.193) -1.0 92 (0.076) -5.5 
1.4 138 (0.179) -0.3 107 (0.096) -8.1 
2.7 127 (0.211) -2.3 86 (0.043) -17.2 
pAA 
1.3 132 (0.187) -1.1 98 (0.086) -3.4 
1.9 133 (0.210) -0.6 107 (0.085) -5.1 
5.1 130 (0.165) -2.0 123 (0.195) -10.2 
a) ratio normalized to poly(N-isopropylacrylamide) content, quantified via pH titration. 
b) measured in PBS (10 mM , pH 7.4)
The NGs were monodisperse and maintained the typical thermoresponsive behavior of 
pNIPAM, showing a shrinkage in volume of about 67% at 45 °C. UV-VIS spectroscopy revealed 
cloud point temperature (Tcp) values of 33 °C for all samples, in agreement with the values 
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obtained by dPG-pNIPAM NGs prior to semi-interpenetration. As expected from the synthetic 
approach, the semi-interpenetration was not affecting the thermoresponsive behavior of the 
NGs. After semi-interpenetration with both pABC (pKa = 5) and pAA (pKa = 4.2), NGs exhibit 
temperature-dependent ζ-potential variations at a neutral pH of 7.4. By increasing the 
temperature above the LCST of pNIPAM (33 °C), NGs turned from neutral to negatively 
charged. This finding was interpreted as an indication for pABC or pAA being exposed at the 
NGs surface after NG shrinkage. Sharp, reversible ζ-potential transitions with changing 
temperature were observed, for samples with at least 1.4 mol% pABC or 1.9 mol% pAA, as 
shown in Fig. 2. The inflection of the data points was highest at 32 °C, compatible with the 
LCST of pNIPAM, while the Δζ values between 25 °C and 45 °C were proportional to the SIPN 
concentrations. In this way, the SIPN provided new temperature-dependent charge density 
fluctuations in the NGs, which were then exploited as on-demand switchable protein binding 
moieties. 
Fig. 2 Evolution of ζ-potential values with temperature, measured at pH 7.4 in a 10 mM sodium 
phosphate buffer for semi-interpenetrated poly(4-acryloylamine-4-(carboxyethyl)heptanodioic 
acid) (left) and poly(acrylic acid)  (right) nanogels. 
By comparing 1H-NMR spectra of pABC SIPN NGs at 25 °C and 45 °C, both above and below 
the LCST of pNIPAM, the spectra revealed significant changes in the peak intensities of the 
different polymers. In Fig. 3 it can be visualized how the peaks representing pNIPAM (δ = 0.8 
– 2.1; δ = 3.8 ppm) are strongly decreasing at 45 °C as compared to those detected at 25 °C.
The peak intensities for dPG (δ = 3.4 – 3.7; δ = 3.9 ppm) and pABC at δ = 2.3 ppm remained 
in turn mostly constant after temperature increase. This observation corroborates the previous 
finding that pABC chains and dPG are surface-active after the collapse of pNIPAM.  
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Fig. 3 1H-NMR spectra in D2O of 2.7 mol% poly(4-acryloylamine-4-(carboxyethyl)heptanodioic 
acid) semi-interpenetrated nanogels at 25 °C (blue line) vs 45 °C (red line). 
Cyt c corona formation and in vitro release kinetics 
The ability to expose charges on the surface of the NGs triggered by temperature change 
allowed the use of SIPN NGs as agents for reversible electrostatic binding of proteins. At 37 
°C and pH 7.4 the NGs achieve maximum exposure of negatively charged pABC (or pAA), an 
ideal setting for the binding of basic proteins. A cyt c corona was thus easily formed by 
electrostatic pairing of the positively charged protein with negatively charged pABC (or pAA) 
on the NG surface. Although the collapsed NGs were ideally not contributing to encapsulation, 
loading capacities were found to be high, with values found in a range of 50-70 wt% for SIPN 
pABC NGs and 70-80 wt% for SIPN pAA NGs, starting from an initial 1:1 w/w cyt c/NG ratio. 
After the cyt c corona formation, release kinetics were determined both at a constant 
temperature of 37 °C and by cooling down to 25 °C, to investigate whether the swelling of NGs 
would lead to the disruption of the corona and thereby cause cyt c release. The kinetics data 
is shown in Fig. 4. 
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Fig. 4 Cytochrome c release kinetics for semi-interpenetrated poly(4-acryloylamine-4-
(carboxyethyl)heptanodioic acid) nanogels (left), semi-interpenetrated poly(acrylic acid) 
nanogels (right).  
For pABC SIPN NGs, a distinct boost in the release was observed by cooling down the 
samples to 25 °C, as compared to the release values obtained at 37 °C, in samples with at 
least 0.9 mol% pABC. In this case, the swelling of the NGs efficiently boosted the release of 
cyt c, thereby acting as a trigger. For samples having less than 0.9 mol% pABC, the SIPN 
concentration might have been too low to observe any difference in release kinetics, just as 
they did not show strong ζ-potential changes above and below 32 °C (see Fig. 2). The release 
kinetics for pAA SIPN NGs however were almost independent from the experimental 
temperature, with a slight increase at 37 °C. Although a sustained release in a 24 h interval 
was still present in this case, the kinetics curves resemble those observed for cyt c alone, 
although with increasing half - lives. Thus, the driving force for cyt c release by AA SIPN NGs 
may be attributed to simple diffusion, with no contribution from NG swelling. For pAA-cyt c 
samples, a slower release and 25% higher loadings might indicate a stronger binding than in 
pABC-cyt c samples, with comparable SIPN polymer concentrations / -COOH groups. 
Therefore, these findings suggest an anti-cooperative effect for the binding of cyt c by dendritic 
pABC, that ultimately yielded an optimal reactivity for the reversible binding of cyt c. Control 
non-SIPN NGs had a lower cyt c loading (16 wt%) and a very fast release behavior, with more 
than 70% cyt c released within 4 h, independently from the experimental temperature (see SI). 
Furthermore, cyt c’s structural integrity was confirmed after release by circular dichroism 
measurements (see SI). 
Induction of apoptosis in HeLa cells 
To confirm the controlled binding and triggered release of cyt c in a biological context, we 
investigated the ability of the loaded SIPN NGs to induce apoptosis in HeLa cells. The NGs, 
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both loaded with cyt c and unloaded as a control, were first incubated at 37 °C for 2 h with 
HeLa cells to allow cellular uptake of the NG at the physiologically optimal temperature. Then 
the temperature was lowered to 30 °C, allowing a prolonged release of cyt c for 16 h, while a 
parallel sample set was kept at 37 °C, where release of cyt c should be strongly sustained. In 
the last step, all samples were incubated at 37 °C for 4 h, in order to allow sufficient time at 
physiologically optimal temperature for the induction of apoptosis, which was measured by 
quantifying caspase 3/7 activation (Fig. 5). 
Fig. 5 Apoptosis assay on HeLa cells after incubation with semi-interpenetrated 2.7 mol% 
pABC (top) and 5.1 mol% pAA nanogels (middle). The release of cytochrome c from 2.7 mol% 
pABC nanogels was efficiently boosted by swelling of the nanogels at 30 °C, thereby activating 
apoptosis in HeLa cells (bottom). 
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We could clearly observe that apoptosis was promoted only in presence of cyt c-loaded 2.7 
mol% pABC NG, and the effect was greatly amplified at 30°C, where full NG swelling occurred. 
This effect of the NG swelling had an impact on the cyt c release in vitro, which activated 
apoptosis in HeLa cells. 2.7 mol% pABC SIPN NG with cyt c concentrations as low as 20 nM 
were promoting apoptosis at 30 °C, while no significant effect was observed by increasing cyt 
c concentration. At 37 °C, a minimum cyt c concentration of 200 nM was necessary to observe 
any effect on apoptosis, which was slightly enhanced by increasing towards 2 μM cyt c. While 
a slight increase in apoptosis was generated by 5.1 mol% pAA SIPN NG, independently from 
the cyt c loading, no effect was detected in combination with cyt c. In this case, no efficient 
cytosolic delivery of cyt c might have occurred, possibly due to a too strong pAA-cyt c binding. 
Again, the careful choice of SIPN polymer showed an impact on the therapeutic efficacy of 
SIPN NGs as cyt c carriers for controlled apoptosis. 
Conclusions 
In this work, we synthesized SIPN NGs by a simple one-pot strategy, with the aid of free-radical 
polymerization, where the previously synthesized NGs were used as scaffold to hold the 
resulting SIPN. The polymerization of ABC monomer achieved SIPN NGs with repetitive 
dendritic charged units, which were found to be exposed to the NG surface above 33 °C, as 
shown by DLS and 1H-NMR spectroscopy. By exposing charges at 37 °C, we were able to 
form a cyt c corona by electrostatic pairing between pABC and cyt c. An identical procedure 
was employed for the synthesis of pAA SIPN NGs and subsequent cyt c corona formation, in 
order to compare the protein binding behavior between monovalent and dendritic SIPNs. The 
stability of the cyt c corona was investigated in relation with the NG swelling in vitro, where a 
boost in the release of cyt c was observed for SIPN pABC NGs when cooled down to room 
temperature. By maintaining a higher temperature of 37 °C, the cyt c corona was in fact more 
stable and the cyt c release was decreased. For monofunctional control pAA SIPN NGs, we 
could not observe any relevant contribution from NG swelling on the release, as the cyt c 
release mechanism appeared as simple diffusion. Moreover, the pAA SIPN NGs showed a 
stronger binding of cyt c than pABC SIPN NGs, as seen by 25% higher loadings and overall 
slower cyt c release kinetics. The use of a dendritic polymer (pABC) helped decreasing the 
binding affinity to an extent that was optimal for compensating the mechanical forces arisen 
from NG swelling, thus achieving full on-demand control of loading / release of cyt c upon 
thermal trigger. In order to demonstrate their potential for controlled delivery applications, a cyt 
c corona was assembled on SIPN NGs, which could successfully promote apoptosis in HeLa 
cells. The activation of the intrinsic apoptotic pathway following cyt c cytosolic delivery was 
observed only in presence of cyt c-loaded 2.7 mol% pABC SIPN NG, the effect being strongly 
enhanced by full NG swelling, induced by applying moderate cooling to 30 °C. Overall, these 
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findings showed that the choice of dendritic SIPN polymer and concentration was crucial for 
the modulation of the cyt c binding / release. We therefore achieved full controlled reactivity of 
dendritic SIPN NGs as carriers for the apoptotic reagent cyt c, its activation being regulated by 
a simple thermal trigger. By performing a similar set of experiments with SIPN NGs binding the 
acidic protein asparaginase (pI = 5.5), we unfortunately observed aggregation of all samples. 
Nevertheless, a similar approach may show potential for the reversible binding of other proteins 
of interest. 
Overall, we believe that the use of localized cooling agents in combination with 
thermoresponsive NGs and a preassembled protein corona may show promising uses for the 
treatment of superficial tumors as well as skin diseases. The use of therapeutic proteins, 
combined with dendritic thermoresponsive NGs as macromolecular agents, may be beneficial 
in order to reduce side effects of conventional therapeutics as well as to improve the therapy 
specificity.  
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Semi-interpenetrated, dendritic, dual-responsive nanogels with cytochrome c corona induce 
controlled apoptosis in HeLa cells 
Enrico Miceli, Stefanie Wedepohl, Ernesto Rafael Osorio Blanco, Guido Noé Rimondino, 
Marisa Martinelli, Miriam Strumia, Maria Molina, Mrityunjoy Kar, Marcelo Calderón 
Fig. S1. Cytochrome c release kinetics for non-interpenetrated dPG-pNIPAM nanogels. 
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Fig. S2. Circular dichroism spectra of released cytochrome c from nanogels. 
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4. Summary and Conclusion 
This work explored different modalities for the optimization of the properties of 
thermoresponsive nanogels, with regard to their application as drug carriers in anticancer 
therapy. The ability of nanogels to reversibly bind different chemotherapeutic drugs was 
investigated, following different strategies. The main focus was the implementation of synthetic 
procedures that allowed the incorporation of dendritic structures into nanogels, together with 
the design of multicompartimental nanogels as drug carriers with improved versatility. In order 
to successfully translate these synthetic efforts into nanogels showing good in vivo 
compatibility, thermoresponsive nanogels were investigated for their ability to interact with 
blood proteins in physiological conditions. The assessment of the protein corona around 
thermoresponsive nanogels, after their incubation in human serum and plasma, was described 
in Section 3.1 - 3.2 of the present thesis. These studies focused on the understanding of 
polymer – protein associations in physiological conditions with regard to the role of the single 
constituents of thermoresponsive nanogels in the interaction with proteins, namely 
thermoresponsive polymers and dPG. In order to direct the drug carrier to the desired target 
in vivo and prevent its sequestration from the bloodstream, unwanted interactions with 
opsonins at a protein corona level should be avoided. The analysis of such interactions help 
understanding the biocompatibility of thermoresponsive nanogels that are designed for 
intravenous administration, ideally to bridge a gap between in vitro and in vivo assays. While 
both nanogel constituents, dPG and pNIPAM,  are regarded as polymers with very low protein 
affinities,28, 65 their incorporation into nanogels leads to a relevant size increase, which is a 
common factor associated with increased protein binding.56 An in-depth analysis of the protein 
corona of dPG-based thermoresponsive nanogels is thus revealed in this thesis in Section 3.1 
- 3.2. Following the need to optimize nanogels to adjust the biological responses they will 
evoke, the ability to resist unwanted surface interactions with proteins was proven to be 
enhanced in the presence of dPG, as expected from its neutral, hydrophilic character. dPG 
provided colloidal stability to thermoresponsive nanogels, without drastically altering the key 
thermoresponsive properties,71 as well as inhibiting the unspecific absorption of proteins onto 
the nanogels’ surface. The inhibition of the protein binding was so successful that only traces 
of protein were found for these nanogel systems (3 – 7 μg / m2 nanogel). Nevertheless, a 
protein-dependent aggregation for dPG-pNIPAM nanogels was found above their VPTT, as 
revealed by DLS measurements in full human serum at 37 °C. The traces of immunoglobulin 
light chains, found specifically enriched at 37 °C, may signal an immunoglobulin bridging 
between nanogels as driving force for their aggregation, analogous to what was found for 
polystyrene nanoparticle systems in the literature.128 This temperature-dependent protein 
corona study proved the need to optimize the polymer choice for their use in biology, where 
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unspecific protein binding is ruling the final polymer / nanoparticle distribution and blood 
availability. In fact, by changing the polymer from pNIPAM to pNIPMAM, the nanogels were 
found to be safe to use in physiological conditions at 37 °C, as they do not aggregate in serum 
and reach their hydrophobic transition at a higher VPTT of 46 °C. 
The generation of innovative nanogel systems for different applications as responsive drug 
carriers for anticancer therapy is disclosed in Section 3.3 - 3.5 of this thesis. The core of this 
section is the optimization of the synthesis of pH- and / or thermoresponsive nanogels, by 
tuning the dendron / pNIPAM comonomer ratio in copolymer nanogels (Section 3.4) or by 
screening polymer concentrations to obtain an optimal binding strength for the loading and 
sustained release of therapeutic molecules by SIPN nanogels (Sections 3.3, 3.5). Nanogels 
with tunable reactivities are designed using dendritic polymers. Dendritic structures allow for a 
high density of functional groups, that improve nanogel solubility and may mediate multivalent 
effects. The use of dPG as macromolecular crosslinker helped in previous reports to improve 
the biocompatibility of thermoresponsive pNIPAM.71 Linear polymers with tunable responsive 
functionalities / concentrations were used in combination with dendritic moieties, in a 
synergistic effort for the optimization of the nanogels’ biological behavior. The use of the 
nanogels as drug delivery systems was demonstrated for small chemotherapeutic drugs 
(cisplatin and DOX), as well as for cytochrome c as a therapeutic protein.  
The changes in nanogel morphology upon chemical modification were thoroughly investigated, 
in relation with the nanogel’s ability to weakly interact with therapeutic molecules (small drugs 
or proteins). In this way, an optimal tuning of the binding and release kinetics of the loaded 
molecule for efficient drug delivery could be achieved. SIPN nanogels were developed as 
powerful agents for the rational tuning of the interactions between nanogels and the desired 
therapeutic cargo. Most importantly, the introduction of a secondary network to give SIPN does 
not directly interfere with the key responsive properties of nanogels, but rather adds new 
physicochemical responsive modalities. dPG-pNIPAM nanogels were employed as starting 
materials for the generation of SIPN within the nanogel scaffold. In this way, the advantageous 
properties of dPG-pNIPAM nanogels were further tuned, with pABC as dendritic secondary 
polymeric network to achieve SIPN nanogels, which allow the assembly of a therapeutic 
cytochrome c corona. The loaded nanogels showed therapeutic potency against HeLa cells 
which could be specifically triggered by a temperature shift. Here, the swelling of 
thermoresponsive nanogels was used as the mechanical force helping the disruption of the 
supramolecular protein corona and its intracellular delivery into HeLa cells (Section 3.3). The 
use of dendritic ABC was further investigated as comonomer for the synthesis of pABC-co-
pNIPAM nanogels, which introduced pH-responsiveness in addition to the thermoresponsive 
behavior of nanogels. This allowed a sustained release of cisplatin only upon reaching acidic 
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compartments (like lysosomes) of cells (Section 3.4). The copolymerization with ABC 
drastically altered the thermoresponsiveness of the copolymer compared to pNIPAM, to give 
nanogels with VPTT behavior only in acidic conditions (pH < 5), with VPTT values decreasing 
in an ABC concentration-dependent manner. The decrease in the VPTT was related to 
increased intermolecular pABC hydrogen bonding, when pABC was in its protonated state. 
The loading of the nanogels with cisplatin at pH 7.4 resulted in stable ABC-Pt bonds, which 
may be disrupted in acidic conditions, as a consequence of H-bond driven nanogel aggregation 
and subsequent release of the previously bound cisplatin.  
In an analogous approach to that of Section 3.3, SIPN nanogels showed increased affinity 
towards the chemotherapeutic drug DOX, with the aid of p(AMPS) as secondary polymeric 
network within the nanogels, and achieved in vivo anticancer activity in DOX-resistant 
conditions (Section 3.5). The use of AMPS SIPN nanogels could tune the electrostatic binding 
of DOX to the carrier and thereby enable the drug to successfully bypass the resistance 
mechanisms of multidrug resistant tumor cells in vitro and in vivo. 
All areas of the research discussed in this thesis help to unveil relevant discoveries for the 
optimization the properties of soft, stimuli-responsive nanogels, for their application as 
innovative drug carriers. The discoveries published in this work help to push forward the 
implementation of next generation nanogels and to disclose further information about the 
modalities of actions of stimuli-responsive nanogels and their translation into clinical therapies. 
There is no limit for the design of new nanoparticles exhibiting moderate polymer - drug 
interactions for sustained drug release, as long as the polymer - protein interactions are 




In order to push the application of the core findings of this work further, a strong effort is 
currently made to pursue the synthesis of biocompatible soft nanogels that are capable to 
undergo controlled degradation at physiological conditions, to achieve effective clearance from 
the body after accomplishing their therapeutic purpose. To achieve this, disulfide bonds or 
proteolytically cleavable bonds are usually introduced within the core nanogel structure, that 
are susceptible to degradation, to give smaller polymer chains / particles that may be excreted 
ultimately by the kidneys. A strong synthetic effort is needed in this sense to prevent 
nanoparticle accumulation in the body, which may result in long-term toxicity issues. 
At the same time, the findings about the protein corona published in this thesis do not cover 
the interaction between a self-assembled corona and the release kinetics of a loaded 
biomolecule from the nanogels. In a way, the presence of a protein corona may counteract a 
too fast release of cargo and meliorate the overall nanogel performance in specific cases, due 
to the steric crowding of nanogels by protein coating layers. Nevertheless, a sustained release 
kinetics in vitro in absence of proteins may signify a too slow release in presence of a protein 
corona. It is thus strongly suggested to perform drug release studies in presence of a protein 
corona, as it reflects more closely the physiological conditions in which nanogels are designed 
to perform.124, 125, 171  
An example of a preassembled protein corona with therapeutic efficacy shown in Section 3.3 
opens a range of new unanswered questions, regarding the intrinsic therapeutic potency of 
protein coronae that are spontaneously formed around nanogels, and their potential as stand-
alone drugs. A protein corona-dependent aggregation of dPG-pNIPAM above its VPTT 
observed in Section 3.1 may be a model case study to generate localized toxicity upon 
temperature-induced aggregation by thermoresponsive nanogels.  
The systematic studies about the characterization of protein coronae may be further extended 
to SIPN or copolymer nanogels in future studies. As the presence of a SIPN shows increased 
stiffness of nanogels, this may influence the protein corona composition unpredictably, upon 
incubation of nanogels in blood plasma and / or serum. The presence of a hydrophobic or 
charged SIPN polymer may lead to an increase in protein absorption and change in 
composition of the corona, thus it should be considered as a direct follow-up study from this 
thesis. 
The wise choice of polymer structure, nanogel architecture and interactions with environmental 
conditions are the main requirements for the successful development of macromolecular 
therapeutic agents. The tailoring of these properties synergistically helps to define the protein 
corona structure that is expected upon contact with any biological fluid, and translates the 
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nanoparticle’s chemical structure to its in vivo behavior. The synthetic strategies employed in 
this work may be further optimized through their protein coronae outcomes, to give performing 
nanogels structures with improved therapeutic responses.    
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6. Kurzzusammenfassung und Ausblick 
Die Grundlage dieser Arbeit war die Untersuchung verschiedener Modalitäten zur Optimierung 
der Eigenschaften von thermoresponsiven Nanogelen hinsichtlich ihrer Anwendung als 
Wirkstoffträger in der Krebstherapie. Die Fähigkeit von Nanogelen verschiedene 
Chemotherapeutika reversibel zu binden wurde mit verschiedenen Strategien untersucht. Das 
Hauptaugenmerk lag auf der Implementierung von Synthesemethoden, die den Einbau von 
dendritischen Strukturen in Nanogele ermöglichten, sowie das Design multikompartimenteller 
Nanogele als Wirkstoffträger mit verbesserter Anpassungsfähigkeit. Um diese synthetischen 
Anstrengungen erfolgreich in Nanogele mit guter In-vivo-Kompatibilität umzusetzen, wurde die 
Interaktion von thermoresponsiven Nanogelen mit Blutproteinen unter physiologischen 
Bedingungen untersucht. Die Untersuchung der Proteinkorona, die sich um thermoresponsive 
Nanogele nach ihrer Inkubation in Humanserum und Plasma bildet, wurde in Abschnitt 3.1 - 
3.2 der vorliegenden Arbeit beschrieben. Diese Studien konzentrierten sich auf das 
Verständnis von Polymer-Protein-Assoziationen unter physiologischen Bedingungen in Bezug 
auf die Rolle der einzelnen Bestandteile thermoresponsiver Nanogele bei der Wechselwirkung 
mit Proteinen, nämlich thermoresponsive Polymere und dPG. Damit der Wirkstoffträger in vivo 
das gewünschte Ziel erreicht und um dessen Sequestrierung aus dem Blutstrom zu 
verhindern, sollten unerwünschte Wechselwirkungen mit Opsoninen vermieden werden. Die 
Analyse solcher Wechselwirkungen hilft, die Biokompatibilität von thermoresponsiven 
Nanogelen zu verstehen, die für intravenöse Verabreichungen konzipiert sind und 
idealerweise schließen sie damit die Lücke zwischen In-vitro- und In-vivo-Assays. Während 
beide Nanogel-Bestandteile, dPG und pNIPAM, als Polymere mit sehr geringen 
Proteinaffinitäten angesehen werden, 28, 65 führt ihr Einbau in Nanogele zu einer relevanten 
Größenzunahme, welche häufig auf eine erhöhte Proteinbindung hinweist.56 Es konnte gezeigt 
werden, dass unerwünschte Oberflächenwechselwirkungen mit Proteinen in Gegenwart von 
dPG verringert werden, was durch den neutralen, hydrophilen Charakter zu erwarten ist. dPG 
vermittelt kolloidale Stabilität der thermoresponsiven Nanogele ohne die wichtigen 
thermoresponsiven Eigenschaften drastisch zu verändern71 und hemmt die unspezifische 
Anlagerung von Proteinen an die Oberfläche der Nanogele. Die Hemmung der Proteinbindung 
war so erfolgreich, dass für diese Nanogelsysteme nur Spuren von Proteinen (3 - 7 μg/m2 
Nanogel) gefunden wurden. Nichtsdestotrotz wurde eine Protein-abhängige Aggregation für 
dPG-pNIPAM-Nanogele oberhalb ihrer VPTT gefunden, wie durch DLS-Messungen in vollem 
Humanserum bei 37 ° C beobachtet wurde. Die Spuren leichter Ketten des Immunglobulins, 
die bei 37 °C spezifisch angereichert wurden, weisen auf eine Quervernetzung mit 
Immunoglobulinen zwischen Nanogelen als Triebkraft für deren Aggregation hin;  analog zu 
dem, was in der Literatur für Polystyrol-Nanopartikelsysteme gefunden wurde. 128 Diese 
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temperaturabhängige der Proteinkorona hat die Notwendigkeit aufgezeigt, die Wahl des 
Polymers für die Verwendung in der Biologie zu optimieren, wo die unspezifische 
Proteinbindung die Serumverfügbarkeit und endgültige systemische Verteilung von 
Polymer/Nanopartikeln bestimmt. Tatsächlich erwiesen sich die Nanogele durch die 
Veränderung des Polymers von pNIPAM zu pNIPMAM als sicherer für die Anwendung unter 
physiologischen Bedingungen bei 37 °C, da sie nicht im Serum aggregieren und ihren 
hydrophoben Übergang bei einer höheren VPTT von 46 °C erreichen.  
Die Erzeugung von innovativen Nanogelsystemen für verschiedene Anwendungen als 
responsive Wirkstoffträger für die Krebstherapie ist in Abschnitt 3.3 - 3.5 dieser Arbeit 
beschrieben. Der Kern dieses Abschnitts ist die Optimierung der Synthese von pH- und/oder 
thermoresponsiven Nanogelen durch Abstimmen des Dendron/pNIPAM-Comonomer 
Verhältnisses in Copolymer-Nanogelen (Abschnitt 3.4) und durch Untersuchung einer 
systematischen Reihe verschiedener Polymerkonzentrationen, um eine optimale 
Bindungsstärke für die Beladung und kontinuierliche Freisetzung von therapeutischen 
Molekülen durch SIPN-Nanogele (Abschnitte 3.3, 3.5) zu erhalten. Nanogele mit 
abstimmbaren Reaktivitäten werden hierbei mit dendritischen Polymeren konzipiert. 
Dendritische Strukturen erlauben eine hohe Dichte an funktionellen Gruppen, die die 
Löslichkeit von Nanogelen verbessern und multivalente Effekte vermitteln können. Die 
Verwendung von dPG als makromolekularer Vernetzer half in früheren Berichten die 
Biokompatibilität von thermoresponsivem pNIPAM zu verbessern.71 Lineare Polymere mit 
abstimmbaren reaktiven Funktionalitäten/Konzentrationen wurden in Kombination mit 
dendritischen Einheiten verwendet, um in einer synergistischen Anstrengung das biologische 
Verhalten der Nanogele zu optimieren. Die Verwendbarkeit der Nanogele als 
Wirkstofftransportsystem wurde für kleine Chemotherapeutika (Cisplatin und DOX) sowie für 
Cytochrom c als therapeutisches Protein belegt.  
Die Veränderungen der Nanogel-Morphologie während der chemischen Modifikation wurden 
eingehend untersucht, insbesondere im Zusammenhang mit der Fähigkeit des Nanogels mit 
therapeutischen Molekülen (kleinen Wirkstoffen oder Proteinen) schwach zu interagieren. Auf 
diese Weise konnte eine optimale Abstimmung der Bindungs- und Freisetzungskinetik des 
geladenen Moleküls für eine effiziente Wirkstoffabgabe erreicht werden. SIPN-Nanogele 
wurden als leistungsstarke Kandidaten für die rationale Abstimmung der Wechselwirkungen 
zwischen Nanogelen und den gewünschten eingelagerten Wirkstoffe entwickelt. Ein 
bedeutender Punkt war die Einführung eines sekundären Netzwerkes, um das SIPN zu 
erhalten und dabei nicht direkt mit den responsiven Eigenschaften der Nanogelen zu 
interferieren, sondern vielmehr neue physikochemisch responsive Modalitäten hinzuzufügen. 
dPG-pNIPAM-Nanogele wurden als Ausgangsstoffe für die Erzeugung von SIPN im Nanogel-
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Gerüst eingesetzt. Auf diese Weise wurden die vorteilhaften Eigenschaften von dPG-pNIPAM-
Nanogelen weiter abgestimmt, wobei pABC als dendritisches sekundäres polymeres Netzwerk 
zum Aufbau von SIPN-Nanogelen diente, das die Anlagerung einer therapeutischen 
Cytochrom-c-Korona ermöglichte. Die beladenen Nanogele zeigten eine therapeutische 
Wirksamkeit gegen HeLa-Zellen, die spezifisch durch eine Temperaturverschiebung ausgelöst 
werden konnte. Hier wurde das Aufquellen von thermoresponsiven Nanogelen als 
mechanische Kraft verwendet, um die Auflösung der supramolekularen Proteinkorona und 
deren intrazelluläre Freisetzung in HeLa-Zellen zu unterstützen (Abschnitt 3.3). Weiterhin 
wurde die Verwendung von dendritischem ABC als Comonomer für die Synthese von pABC-
co-pNIPAM-Nanogelen untersucht, die zusätzlich zum thermoresponsiven Verhalten von 
Nanogelen eine Sensitivität gegenüber Änderung des pH-Wertes einführten. Dies ermöglichte 
eine kontinuierliche Freisetzung von Cisplatin erst bei Erreichen von sauren Kompartimenten 
(wie Lysosomen) in den Zellen (Abschnitt 3.4). Die Copolymerisation mit ABC veränderte die 
Thermoresponsivität des Copolymers im Vergleich zu pNIPAM drastisch. Die erhaltenen 
Nanogele zeigten ihr typisches VPTT-Verhalten nur unter sauren Bedingungen (pH <5), wobei 
die VPTT-Werte in Abhängigkeit der ABC-Konzentration abnahmen. Die Abnahme der VPTT 
war auf erhöhte intermolekulare pABC-Wasserstoffbrücken zurückzuführen, wenn sich pABC 
im protonierten Zustand befand. Die Beladung der Nanogele mit Cisplatin bei pH 7,4 führte zu 
stabilen ABC-Pt-Bindungen, die unter sauren Bedingungen als Folge der durch 
Wasserstoffbrücken induzierten Nanogelaggregation gebrochen wurden, und anschließender 
Freisetzung des zuvor gebundenen Cisplatin.  
In einem analogen Ansatz wie in Abschnitt 3.3 zeigten SIPN Nanogele mit Hilfe von p(AMPS) 
als sekundäres polymeres Netzwerk innerhalb der Nanogele eine erhöhte Affinität gegenüber 
dem chemotherapeutischen Wirkstoff DOX und waren somit in der Lage, antitumorale Wirkung 
gegenüber DOX-resistenten Tumorzellen in vitro und in vivo zu vermitteln (Abschnitt 3.5).  
Die in dieser Arbeit veröffentlichten Erkenntnisse tragen dazu bei, die Implementierung von 
Nanogelen der nächsten Generation voranzutreiben, weitere Informationen über die 
Modalitäten der Wirkungen von auf Stimuli reagierenden Nanogelen zu offenbaren und zu 
deren Übertragung in klinische Therapien beitragen. Es gibt keine Grenzen für die 
Implementierung neuer Nanopartikel, die moderate Wechselwirkungen zwischen Polymeren 
und Wirkstoffen für eine nachhaltige Freisetzung von Arzneimitteln nutzen, solange die 
Wechselwirkungen zwischen Polymer und Protein identifiziert werden und Kompatibilität mit 
dem beabsichtigten therapeutischen Zweck zeigen. 
Um die Umsetzung der Kernergebnisse dieser Arbeit weiter voranzutreiben, wird derzeit 
intensiv an der Synthese von biokompatiblen weichen Nanogelen gearbeitet, die unter 
physiologischen Bedingungen einem kontrollierten Abbau unterlaufen können, um eine 
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wirksame Ausscheidung aus dem Körper zu erreichen, nachdem sie ihren therapeutischen 
Zweck erfüllt haben. Um dies zu erreichen, werden üblicherweise Disulfidbindungen oder 
proteolytisch spaltbare Bindungen in die Nanogelstruktur eingebracht, die zum Abbau der 
Nanogele zu kleineren Polymerketten/-partikeln führen, die letztendlich von den Nieren 
ausgeschieden werden können. In diesem Sinne ist ein großer synthetischer Aufwand 
erforderlich, um eine Akkumulation von Nanopartikeln im Körper zu verhindern, was zu 
langfristigen Toxizitätsproblemen führen kann.  
Die in dieser Arbeit veröffentlichten Erkenntnisse über die Proteinkorona decken nicht die 
Interaktion zwischen einer selbstorganisierten Korona und der Freisetzungskinetik geladener 
Biomoleküle aus den Nanogelen ab. In gewisser Weise kann das Vorhandensein einer 
Proteinkorona einer zu schnellen Freisetzung der geladenen Therapeutika entgegenwirken 
und dadurch die Leistungsfähigkeit der Nanogele in bestimmten Fällen aufgrund sterischer 
Hinderung von Nanogelen durch die Proteinschichten verbessern. Nichtdestotrotz kann eine 
kontinuierliche Freisetzungskinetik in vitro in Abwesenheit von Proteinen eine zu langsame 
Freisetzung in Gegenwart einer Proteinkorona bedeuten. Es empfiehlt sich daher, 
Wirkstofffreisetzungsstudien in Gegenwart einer Proteinkorona durchzuführen, da sie die 
physiologischen Bedingungen, unter denen Nanogele wirken sollen, genauer darstellen.124, 125, 
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Ein Beispiel für eine vorher zusammengesetzte Proteinkorona mit therapeutischer 
Wirksamkeit, die in Abschnitt 3.3 vorgestellt wurde, eröffnet eine Reihe neuer 
unbeantworteter Fragen bezüglich der intrinsischen therapeutischen Potenz von 
Proteinkoronen, die sich spontan um Nanogele bilden und deren Potenzial als eigenständige 
Wirkstoffe. Eine Proteinkorona-abhängige Aggregation von dPG-pNIPAM oberhalb der VPTT 
wie in Abschnitt 3.1 beobachtet, kann eine Modellfallstudie sein, um lokalisierte Toxizität bei 
temperaturinduzierter Aggregation durch thermoresponsive Nanogele zu erzeugen.  
Die systematischen Untersuchungen über die Charakterisierung von Proteinkoronen können 
in zukünftigen Studien auf SIPN- oder Copolymer-Nanogele ausgeweitet werden. Da das 
Vorhandensein eines SIPNs eine erhöhte Steifigkeit von Nanogelen bewirkt, kann dies die 
Proteinkorona-Zusammensetzung bei der Inkubation der Nanogele in Blutplasma und/oder 
Serum unvorhersehbar beeinflussen. Die Anwesenheit eines hydrophoben oder geladenen 
SIPN-Polymers kann zu einer Zunahme der Proteinadsorption und zu einer Änderung der 
Zusammensetzung der Korona führen und sollte daher als direkte Folgeuntersuchung aus 
dieser Arbeit betrachtet werden.  
Die sinnvolle Wahl der Polymerstruktur, Nanogel-Architektur und Wechselwirkungen mit 
Umweltbedingungen sind die Hauptanforderungen für die erfolgreiche Entwicklung von 
makromolekularen Therapeutika. Das Zuschneiden dieser Eigenschaften hilft synergistisch, 
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die Proteinkorona-Struktur zu definieren, die bei Kontakt mit einer biologischen Flüssigkeit zu 
erwarten ist und übersetzt die chemische Struktur des Nanopartikels in sein Verhalten in vivo. 
Die in dieser Arbeit verwendeten Synthesestrategien können mit den Ergebnissen der 
Untersuchungen der Proteinkorona weiter optimiert werden, um die Struktur des Nanogels und 
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